1.

Name (Mr / Mrs):

(Full name in BLOCK LETTERS)

2. Designation:

3. DOJ:

4. Department / Process:

5. Present Address & Contact No:

6. Permanent Address & Contact No:

7. Emergency Contact Name & Contact No:

(Signature of Candidate)

Date (dd/mm/yy): Name:

1 Name (in Block Letters) :

2 Father’s/Husband’s Name :

3 Date of birth :

4 Sex :

5 Marital Status :

6 Account No. (PF/EPS Number) :

7 Address (Residential) :

Name and Address of the Nominees Date of Birth Total amount of If the nominee is minor, name and
nominee/nominees relationship share relationship and address of the
with the o guardian who may receive the amount
member f during the minority of nominee
accumulations
is Provident
Fund to be paid
to each
nominee (%)
(1) (2) (3) (4) (5)

1 * Certified that I have no family as defined in para 2(g) of the Employees’ Provident Funds Scheme, 1952, and should I
acquire a family hereafter, the above nomination should be deemed as cancelled.
2 * Certified that my father/mother is/are dependent upon me.
3. * Strike out whichever is not applicable.
X----------------------------------------------------------------
Signature or thumb impression of the
 Name of Address of the family member Date of Relationship with
S. No. Address
Name Birth member
(1) (2) (3) (4) (5)

* *Certified that I have no family as defined in pare 2 (vii) of Employee's Pension Scheme, 1995 and should acquire a family here
after I shall furnished particulars thereon in the above form.

I hereby nominate the following persons for receiving the monthly widow pension (admissible under para 16 2(a) (i) and (ii) of Employees’
Pension Scheme, 1995 in the event of my death without leaving any eligible family member for receiving Pension. $$

Name and address of the Nominee, Date of Birth Relationship with the member
(1) (2) (3)

Dated the

X
**Strike out whichever is not applicable. Signature or thumb impression of the subscriber

CERTIFICATE BY EMPLOYER

Certified that the above declaration and nomination has been signed thumb impressed before me by Shri/Smt/Kum DESETTI
SIVASAI KUMAR employed in my establishment after he/she has read the entries have been read over to him/her by me and got
confirmed by him/her.

Place: Vizag Nasir Pasha

Dated the 216102

XX
Signature of the Employer or other authorized Officer of the establishment
Designation Associate, People Solutions
Name & Address of the Factory/Establishment or Rubber Stamp there of
 1. Name of the member

2. Father’s Name Spouse’s

Name (Please tick whichever is
applicable)
3. Date of Birth: ( DD / MM / YYYY )
4. Gender: (Male/Female/Transgender)
5. Marital Status: (Married/Unmarried/Widow/Widower/Divorcee)
6 (a) Email ID:

(b) Mobile No.:

7 Whether earlier a member of Employees’ Provident Fund Scheme, 1952 
8 Whether earlier a member of Employees’ Pension Scheme, 1995 
Previous employment details: [if Yes to 7 AND/OR 8 above]
a) Universal Account Number:
b) Previous PF Account Number:
9 c) Date of exit from previous employment: (DD/MM/YYYY)
d) Scheme Certificate No. (if issued)
e) Pension Payment Order (PPO) No. (if issued)
a) International Worker:
b) If yes, state country of origin (India/Name of other country)
10 c) Passport No.
d) Validity of passport [(DD/MM/YYYY) to (DD/MM/YYYY)]
KYC Details: (attach self-attested copies of following KYCs)
a) Bank Account No. & IFC Code
11 b) AADHAR Number
c) Permanent Account Number (PAN), if available
UNDERTAKING
1) Certified that the particulars are true to the best of my knowledge.
2) I authorize EPFO to use my Aadhar for verification/authentication/e-KYC purpose for service delivery.
3) Kindly transfer the funds and service details, if applicable, from the previous PF account as declared above to the present
P.F. Account. (The transfer would be possible only if the identified KYC detail approved by previous employer has been
verified by present employer using
his Digital
Signature Certificate)
4) In case of changes in above details, the same will be intimated to employer at the earliest.

Date:
Place: Vizag Signature of Member

DECLARATION BY PRESENT EMPLOYER

A. The member Mr./Ms/Mrs. ………………………………….. has joined on ..................................................and has been allotted PF
Number
………………………………….
B. In case the person was earlier not a member of EPF Scheme, 1952 and EPS, 1995:

(Post allotment of UAN) The UAN allotted for the member is ……………………………………
Please Tick Appropriate Option:
The KYC details of the above member in the UAN database
 Have not been uploaded
 Have been uploaded but not approved
 Have been uploaded and approved with DSC
C. In case the person was earlier a member of EPF Scheme, 1952 and EPS, 1995:
The above PF Account Number/UAN of the member as mentioned in (A) above has been tagged with his/her
UAN/Previous Member ID as declared by member
Please Tick the Appropriate Option:-
 The KYC details of the above member in the UAN database have been approved with E-sign/Digital
Signature Certificate and transfer request has been generated on portal.
 As the DSC of establishment are not registered with EPFO, the member has been informed to file physical
claim (Form- 13) for transfer of funds from his previous establishment.
Date: Signature of Employer with Seal of Establishment
 CONCENTRIX DAKSH SERVICES INDIA
PVT LTD [Link]-9-13-45-2/9/4(3), WARD NO-
16
7TH FLOOR, SRK DESTINY, VIP ROAD, VIZAG-530003

x DESETTI SAMBA SIVA RAO Father 52 100%

`

VIZAG X

xx

D Hareesh Patnaik
MIG 29 MVP Sector 6 Vizag -
530003
Anand Kumar
MIG 29 MVP Sector 6 Vizag -
530003
VIZAG

xx

NASIR PASHA
216102 ASSOCIATE, PEOPLE SOLUTIONS

X
 FORM-I
NOMINATION AND DECLARATION FORM
(See rule 3)

[Link] of person making nomination

(in block letters)
[Link]'s/Husband's Name

[Link] of Birth
[Link]

[Link] Status

[Link] Address

[Link] Address

I hereby nominate the person(s)/cancel the nomination made by me previously and nominate the person(s) mentioned below to receive
any amount due to me from the employer, in the event to my death.
x
Name of the Address Nominee’s Date of Birth Total amount of share If the nominee is minor,
nominee/nominees relationship with the of accumulations in name, relationship and
member credit to be paid to address of the guardian
each nominee who may receive the
amount during the
minority of nominee.
1 Certified that I have no family, and should I acquire a family (Spouse, Children) hereafter, the above nomination shall be deemed as cancelled.
2 Certified that my father/mother is/are dependent upon me.
3 *Strike out whichever is not applicable.
4 **Family means Dependent Parents / Spouse / Children - As per Payment of Wages Act, 1936

X
Signature or the thumb impression of the
employed person

CERTIFICATE BY EMPLOYER

Certified that the above declaration and nomination has been signed/thumb impressed before me by

Shri/Smt./Kum employed in my establishment after he/she has read the entry/entries have

been read over to him/her by me and got confirmed by him / her.

xx
NASIR PASHA 216102
ASSOCIATE, PEOPLE SOLUTIONS
Signature of the employer or other authorised officer of
the establishment and Designation

Place: VIZAG
Name and Address of the Factory/Establishment and
Date : rubber stamp thereof.
 DECLARATION FORM FORM - 1
To be filled in the employee after reading instructions overleaf . Two postcard
Size photographs are to be attached with this form .This form is free of cost
AADHAAR NO : * 480373360439
Mobile No * 9491548630
(A) INSURED PERSON's PARTICULARS (B) EMPLOYER'S PARTICULARS
1. Insurance No. if any * 9. Employer's Code No.
R
2. Name (in block letters) * 10. Date of Appointment Day Month Year

3. Father's /Husband's Name * Entry

[Link] of birth * D M Y Marital Status Gender 11. Name & Address of the Employer
26.08.1994 Single MALE CONCENTRIX DAKSH SERVICES INDIA PVT LTD
[Link]-9-13-45-2/9/4(3), WARD NO-16
7. Present Address * 8. Permanent Address *
7TH FLOOR, SRK DESTINY, VIP ROAD, VIZAG-530003

12. In case of any previous employment please fill up the detail

as under :-

Pin Code a) Previous Ins. No.

Pin Code b) Emplr's. Code No.
c) Name & address of the employer

Branch Office : Dispensary *

Detail of Nominee *
Name Relationshi Address
p
DESETTI SAMBA Father 37-12-64/5/A/SF-201, ANJINADRI ENCLAVE, NGOS
SIVA RAO COLONY, NG
,VISAKHAPATNAM,Andhra Pradesh,530007

Bank a/c Details is Mandatory * (in case bank a/c not available can fill bank a/c details of any member of the family which can be
changed subsequently)
Name of Bank Branch Bank A/C No IFSC Code MICR Code

I hereby declare that the particulars given by me are correct to the best of my knowledge and belief . I
undertake to intimate the corporation any charges in the membership of my family within 15 days of
such change.

Counter signature by the employer

216102
Nasir Pasha
Associate, People Solutions
Signature with seal Signature /T.I Of IP

(D) FAMILY PARTICULARS OF INSURED PERSON

Sl. Name Date of Relationship Whether If 'No' state place of Residence

Birth/Age as with the residing Town Aadhaar No State
No. on date of Employe with
filling form e him/her?

1.

2.

3.

4.

5.
…………………………………………………………...……………………………………………………………………………………………………………
……….

ESI Corporation
Temporary Identity Card (valid for 3 months from the date of appointment)
 DESETTI SIVASAI KUMAR
Name

[Link]

Branch Office

Employer's Code No.& Address

V ad
il ti y:
Date d :
21.03.20 Signature/T.I of I.P Signature of B.M. with seal
22
 INSTRUCTIONS

1. Submission of Form -1 is governed by regulations 11 & 12of ESI (General) Regulations, 1950

2. "family" means all or any of the following relatives of an insured Person namely :-
(I) a spouse (ii) a minor legitimate or adopted child dependent upon the I.P.; (iii) a child who is wholly dependant on the earnings of the
I.P. and who is (a ) receving educations , till he or she attains the age of 21 years ( b ) an unmarried
daughter ; ( iv ) a child who is infirm by reason of any physical or mental abnormality or injury and is
wholly dependant on the earnings of the I.P. so long as the infirmity continues ; ( v ) dependant parents (
Please see Section 2 clause 11 of the ESI Act 1948 for details).

3. Identity Card is Non - transferable.

4. Loss of Identity Card be reported to Employer/Branch Manager immediately.

5. Submission of false information attracts penal action under Section 84 of ESI Act,1948.

6. This form duly filled in must reach the concerned Branch Office within 10days of appointment of an
Employee. Delayattracts penal action under Section 85 for the Act, against employer.

7. As an insured person you and your dependent family members are entitled to full medical care . The
other benefit incase include ( 1 ) Sickness benefit ( 2 ) Temporary Disablement Benefit ( 3 ) permanent
Disablement Benefit ( 4 )Dependents benefit and ( 5 ) Maternity Benefit ( in case of women
employees ) subject to fulfillment of contributory conditions.

8. For more details please visit website of ESIC at [Link] or contact Regional office or Branch Office.
9. All * mark filed are mandatory name should be as per aadhaar of employee and member's of family

………………………………………………….…………………………………………………………………………………………………………
……………………..
 CONFLICT OF INTEREST DISCLOSURE FORM

DESETTI SIVASAI KUMAR Vizag WHEELZ

Name (please print) Location and Department

Representative, Operations

Date 21.03.2022 Job Title

It is the policy of Concentrix Corporation and each of its subsidiaries and affiliates (the ―Company‖) to address how issues of
actual, potential and perceived conflicts of interest involving employees of the Company should be identified, disclosed and
managed. This form is designed to identify and disclose such conflicts in an effort to properly manage them.

I have read the Company Code of Ethical Business Conduct and understand that as an employee of the Company
it is my obligation to act in a manner which promotes the best interests of the Company and to avoid conflicts of interest
when making decisions and taking actions on behalf of the Company.

My answers to this disclosure form are correctly stated to the best of my knowledge and belief. Should a possible
conflict of interest arise in my responsibilities to the Company, I recognize that I have the obligation to notify the
appropriate designated contact (Manager, People Solutions, or Legal), and to abstain from any participation in the matter
until the Company can determine whether a conflict exists and how that conflict should be resolved. If any relevant
changes occur in my affiliations, duties, or financial circumstances, I recognize that I have a continuing obligation to file
an amended “Conflict of Interest Disclosure Form” with the appropriate contact referenced above.

Signature Date

1. Are you or a member of your immediate family an employee or consultant of a customer or vendor that presently has material
business dealings with either Concentrix Corporation or any Concentrix subsidiary, (collectively the ―Company‖) or which might
reasonably be expected to have material business dealings with the Company in the coming year? Immediate family is defined as:
spouse, parents and grandparents, children and grandchildren, brothers, sisters, mother-in-law and father-in-law, brother-in-law
and sister-in-law, daughter- in-law and son-in-law, and adopted and step members.

Yes

If yes, please list the name of the customer or vendor, the position held, and the nature of the business which is currently being
conducted with the Company or which may reasonably be expected to be conducted with the Company in the coming year:

February 17, 2021 Page 1

 2. Do you or does any member of your immediate family have a material financial interest, direct or indirect, in a
customer or vendor which currently has material business dealings with the Company or which may reasonably be
expected to have such business dealings with the Company in the coming year?

 Yes No

If yes, please list the name of the customer or vendor, the nature of the interest and the name of the person holding the
interest, and the nature of the business which is currently being conducted with the Company or which may reasonably be
expected to be conducted with the Company in the coming year:

3. Have you or an immediate family member accepted gifts, gratuities, lodging, dining, or entertainment that might
reasonably appear to influence your judgment or actions concerning the business of the Company?

 Yes

If yes, please provide details below:

4. Are you aware of any other facts or circumstances that might reasonably appear to be actual, potential or perceived
conflicts of interest involving employees of the Company?

 Yes

If yes, please provide details below:

February 17, 2021 Page 2

 Receipt and Acknowledgement

I have received a copy of our Company’s Code of Ethical Business Conduct and
have read it carefully. I understand all of the guidelines, practices, and policies
and agree to abide by them.

I understand and agree that if I violate the guidelines, practices, and policies in
the Code of Ethical Business Conduct that I can be disciplined for my conduct
and may even be terminated.

I understand that our Company reserves the right to change, amend, or delete
any or all of the information contained in this Code of Ethical Business Conduct at
any time as dictated by circumstances of the business.

I further understand that signing this Receipt and Acknowledgment form does
not, nor is it intended to, confer any rights or benefits or employment, or
constitute an assurance of continued employment or employment other or
employment other than at will.

Signature:

Date:

Printed Name:

Employee Number:

Company: Concentrix

Locations: Vizag

Waivers of any provision of the Code are generally not permitted and, in any
event, may be granted only by the Board of Directors in writing and must be
disclosed in accordance with applicable law. This Code of Ethical Business
Conduct may be amended from time to time at our Company’s discretion. The
current version of the Code will be posted and maintained on our Company’s
intranet sites and can be obtained from Human Resources or the Legal
Department.

42

Concentrix
Corporation Code of
Ethical Business
Conduct
 Agreement Regarding Confidential Information, Intellectual Property and Other Matters

In consideration of my employment or my continued employment by Concentrix (which includes Concentrix Daksh Services India Private Limited
or Concentrix Services India Private Limited or Concentrix Technologies India Private Limited or Convergys India Services Private Limited as
applicable) which I acknowledge is employment at will, and the payment to me of a salary or other compensation during my employment, I agree
as follow:

1. I will not, without Concentrix’s prior written permission, disclose to anyone outside of Concentrix or use in other than Concentrix’s
business, either during or after my employment, any confidential information or material of Concentrix, or any information or material
received in confidence from third parties, such as suppliers or customers, by Concentrix. If I leave the employment of Concentrix, I will
return to Concentrix all property in my possession belonging to Concentrix or received from any third party by Concentrix, whether or
not containing confidential information, including, but not limited to, diskettes and other storage media, drawings, notebooks, reports,
and other documents.
Confidential information or material of Concentrix is any information or material: (a) generated or collected by or utilized in the
operations of Concentrix , received from any third party, or suggested by or resulting from any task assigned to me or work
performed by me for or on behalf of Concentrix , and (b) which has not been made available generally to the public, whether or not
expressed in a document or other medium and whether or not marked "Concentrix Confidential" or with any similar legend of
Concentrix or any third party. Confidential information or material may include, but is not limited to, information and material related
to past, present and future development, operational activities, or personnel matters; marketing and business plans; technical
specifications, drawings, and designs; prototypes; computer programs; and databases.

2. During my employment with Concentrix and for one year following the termination of my employment for any reason, I will not
directly or indirectly: a) hire, solicit or make an offer to any employee of Concentrix to be employed or perform services outside of
Concentrix; or b) solicit for competitive business purposes any customer of Concentrix with which I have been involved as part of
my job responsibilities during the last year of my employment with Concentrix. I acknowledge that Concentrix would suffer
irreparable harm if I fail to comply with the foregoing.

3. I will not disclose to Concentrix for use in its business, or cause it to use, any information or material which is confidential to any third
party unless authorized by such third party in writing. In addition, I will not incorporate into any services provisioned by Concentrix any
copyrighted materials of any third party, unless authorized by Concentrix.

4. I will comply, and do all things necessary for Concentrix to comply, (a) with the laws and regulations of all governments under which
Concentrix does business, (b) with provisions of contracts between any such government or its contractors and Concentrix that relate to
intellectual property or to the safeguarding of information, and (c) with all of the Concentrix Business Conduct Guidelines as amended
from time to time.

5. This Agreement supersedes all previous oral or written communication, representations, understanding, undertakings, or agreements
relating to the subject matter hereof. Any waiver of a term in this Agreement and any amendment to this Agreement may only be made
in a writing signed by an authorized signatory of Concentrix and myself.

6. Although I may work for the Company outside of India I understand and agree that this Agreement shall be governed by the laws of
India. If any provision of this Agreement is unenforceable by law, the remainder shall remain in effect.

7. I recognize that any violation of my obligations described herein can result in disciplinary action, including dismissal from Concentrix,
and any other appropriate relief for Concentrix including money damages, equitable relief and attorney’s fees.

Signature of the Employee

My Agreement, and my acknowledgment of receipt of a copy of this Agreement, is indicated by my signature below.

Name of Employee: Employee’s Manager/Concentrix Rep: NASIR PASHA

Date (dd/mm/yy):
Date (dd/mm/yy):
Concentrix Signature:
Signature of Employee: X
Employee ID:
Employee ID:

The following are Developments, in which I have any right, title, or interest, and which were previously conceived or written either wholly or
in part by me, but neither published nor filed in any Patent Office:

Title on Document Date on Document Name of Witness on Document

Signed:

Employee's Full Name

Date:

(It is in your interest to establish that any of the above were made, conceived, or written before your employment by Concentrix.
You should not disclose them in detail but identify them only by the titles and dates of documents de-scribing them. If you wish to
draw interest of Concentrix in any of them, you may contact the Intellectual Property and Licensing Department, which will provide
you with instructions for submitting them to Concentrix.)
 PROPRIETARY INFORMATION AND INVENTIONS AGREEMENT

The following Agreement confirms certain terms of my employment with Concentrix (which includes Concentrix Daksh Services India
Private Limited or Concentrix Services India Private Limited or Concentrix Technologies India Private Limited or Convergys India Services
Private Limited as applicable) which is a material part of the consideration for my employment by the Company and the compensation
received by me from the Company from time to time. The headings contained in this Agreement are for convenience only, have no legal
significance, and are not intended to change or limit this Agreement in any matter whatsoever.

A. Definitions

1. The ―Company‖

―Company‖ means Concentrix (which includes Concentrix Daksh Services India Private Limited or Concentrix Services
India private limited or Concentrix Technologies India Private limited or Convergys India Services Private Limited as applicable) and shall
mean and include all its subsidiaries, or affiliated companies.

I recognize and agree that my obligations under this Agreement and all term of this Agreement apply to me regardless of wheth er I am
employed by or work for Concentrix or any other subsidiary or affiliated company of CONCENTRIX. Furthermore, I understand and agree
that the terms of this Agreement will continue to apply to me even if I transfer at some time from one subsidiary or affiliate of Concentrix to
another.

2. ―Proprietary Information‖

I understand that the Company possesses and will possess Proprietary Information which is important to its business. For purposes of this
Agreement, ―Proprietary Information‖ is information that was or will be developed, created, or discovered by or on behalf of the Company, or
which became or will become known by, or was or is conveyed to the Company, which has commercial value in the Company’s business.

―Proprietary Information‖ includes, but is not limited to information about software programs, subroutines and related documentation, source
and object code, algorithms, trade secrets, designs technology, know-how, processes, data, ideas, concept, techniques, inventions (whether
patentable or not), works or authorship, mask works and the like, formulas, business and product development plans, customer lists, terms of
compensation and performance levels of Company employees, Company customers and other information concerning the Company’s ac tual
or anticipated business, research or development, or which is generated, collected or received in confidence by or for the Company from any
other person.

I understand that my employment creates a relationship of confidence and trust between the Company and me with respect to Proprietary
Information.

3. ―Company Documents and Materials‖

I understand that the Company possesses or will possess ―Company Documents and Materials‖ which are important to
its business. For purposes of this Agreement, ―Company Documents and Materials‖ are documents or other media or tangible items that
contain or embody Proprietary Information of any other information concerning the business, operations or plan of the Company, whethe r
such documents, media or items have been prepared by me or by others.

―Company Documents and Material‖ include, but are not limited to, blueprints, drawing, photographs, charts, graphs,
notebook, customer lists, computer disks and other storage media, tapes or printouts, sound recordings and other printed, typ ewritten or
handwritten documents, sample products, prototypes and models.

Signature of Employee
B. Assignment of Rights

All Proprietary Information, and all patents, patent rights, copyrights, trade secret rights, trademark rights and other rights
(including, without limitation; intellectual property rights) anywhere in the world in connection with Proprietary Information, is and shall be
the sole property of the Company. I hereby assign to the Company any and all rights, title and interest I may have or acquire in such
Proprietary Information.
At all times, both during my employment by the Company and after its termination, I will keep in confidence and trust and
will not use or disclose any Proprietary Information or anything relating to it without the prior written consent of an officer of the Company,
except as may be necessary in the ordinary course of performing my duties to the Company.

C. Maintenance and Return of Company Documents and Materials

I agree to make and maintain adequate and current written records, in a form specified by the Company, of all inventions,
trade secrets and works of authorship assigned or to be assigned to the Company pursuant to this Agreement. All Company Documents
and Material are and shall be the sole property of the Company.

I agree that during my employment by the Company, I will not remove any Company Documents and Material from the
business premises of the Company or deliver any Company Document and Materials to any person or entity outside the Company, except
as I am required to do in connection with performing the duties of my employment. I further agree that, immediately upon the termination of
my employment by me or by the Company for any reason, or during my employment if so requested by the Company, I will return all
Company Documents and Material, apparatus, equipment and other physical property, or any reproduction of such property, any third party
information/ Customer related Information whether or not containing confidential Information, including, but not limited to diskettes, and
other storage media, drawings, notebooks, reports, and other documents excepting only (i) my personal copies of records relating to my
compensation; (ii) my personal copies of any material previously distributed generally to stockholders of the Company; and (iii) my copy of
this Agreement.

D. Disclosure of Inventions to the Company

I will promptly disclose in writing to my immediate supervisor or to such other person designated by the Company all
―Inventions,‖ which includes, without limitation, all software programs or subroutines, source or object code, algorithms, improvements,
inventions, works of authorship, trade secrets, technology, designs, formulas, ideas, processes, techniques, know-how and data, whether
or not patentable, made or discovered or conceived or reduced to practice or developed by me, either alone or jointly with others, during
the term of my employment.

I will also disclose to the President of the Company all Inventions made, discovered, conceived, reduced to practice, or
developed by me within six (6) months after the termination of my employment with the Company which resulted, in whole or in part, from
my prior employment by the Company. Such disclosures shall be received by the Company in confidence (to the extent such Inventions
are not assigned to the Company pursuant to Section (E) below) and do not extend the assignment made in Section (E) below.

Signature of Employee
E. Rights to New Ideas

1. Assignment of Inventions to the Company

I hereby assign to Concentrix my entire right, title, and interest in any idea, concept, technique, invention, design, computer programs
and related documentation, other works of authorship, mask works, and the like (all hereinafter called "Inventions"), hereafter made,
conceived, written, or otherwise created solely or jointly by me, whether or not such Inventions are patentable, subject to copyright
protection or susceptible to any other form of protection which: (a) relate to the actual or anticipated business or research or development
of Concentrix or its subsidiaries or (b) are suggested by or result from any task assigned to me or work performed by me for or on behalf
of Concentrix or its subsidiaries.

The above provisions concerning assignment of Inventions apply to Inventions created while I am employed by Concentrix whethe r in an
executive, managerial, professional, product or technical planning, technical, research, programming, or engineering capacity (including
development, product, manufacturing, systems, applied science, and field engineering).

In connection with any of the Inventions assigned as above: (a) I will promptly disclose them in writing to the Concentrix Law
Department; and (b) I will, on Concentrix’s request, promptly execute a specific assignment of title to Concentrix or its designee, and do
anything else reasonably necessary to enable Concentrix or such designee to secure a patent, copyright or other form of protection
therefore in the India and in other countries. In addition, I agree to promptly notify the Concentrix Law Department in writing of any patent
or patent application in which I am an inventor, but which is not assigned as detailed under List of Inventions herein below and which
discloses or claims any Invention made, conceived, or written while I am employed by Concentrix.

Concentrix and its licensees, successors, or assigns (direct or indirect) are not required to designate me as an author of any Invention
which is subject to this Agreement, when it is distributed, publicly or otherwise, or to secure my permission to change or otherwise alter its
integrity. I hereby waive and release, to the extent permitted by law, all rights in and to such designation and any rights I may have
concerning modifications of such Inventions.

I understand that any rights, waivers, releases, and assignments herein granted and made by me are freely assignable by Concentrix
and are for the benefit of Concentrix and its subsidiaries, licensees, successors, and assigns.

2. Works Made for Hire

The Company shall be the sole owner of all patents, patent rights, copyrights, trade secret rights, trademark rights and all
other intellectual property or other rights in connection with Inventions. I further acknowledge and agree that such Inventions, including,
without limitation, any computer programs, programming documentation, and other works of authorship, are ―works made for hire‖ for
purposes of the Company’s rights under copyright laws. I hereby assign to the Company any and all rights, title and interest I may have
or acquire in such Inventions. If in the course of my employment with the Company, I incorporate into a Company product, process or
machine a prior Invention owned by me or in which I have interest, the Company is hereby granted and shall have a nonexclusive,
royalty-free, irrevocable, perpetual, sublicensable, worldwide license to make, have made, modify, use, market, sell, and distribute such
prior Invention as part of or in connection with such product, process or machine.

Signature of Employee

1 |Page CNXALL/ONB/ART/ONBP/PIAIA/1.0
 3. Cooperation

I agree to perform, during and after my employment, all acts deemed necessary or desirable by the Company to permit and
assist it, at the Company’s expense, in further evidencing and perfecting the assignments made to the Company under this Agreement
and in obtaining, maintaining, defending and enforcing patents, patent rights, copyrights, trademark rights, trade secret rights or any other
rights in connection with such Inventions and improvements thereto in any and all countries. Such acts may include, but are not limited
to, execution of documents and assistance of cooperation in legal and proceedings. I hereby irrevocably designate and appoint the
Company and its duly authorized officers and agents, as my agents and attorney-in-fact to act for and on my behalf and instead of me, to
execute and file any documents, applications or related finding and to do all other lawfully permitted acts to further the purposes set forth
above in the Subsection 3, including, without limitation, the perfection of assignment and the prosecution and issuance of patents, patent
applications, copyright applications and registrations, trademark applications and registrations or other rights in connection with such
Inventions and improvements thereto with the same legal force and effect as if executed by me.

4. Assignment or Waiver of Moral Rights

Any assignment of copyright hereunder (and any ownership of a copyright as a work made for hire) include all rights of
paternity, integrity, disclosure and withdrawal and any other rights that may be known as or referred to as ―moral rights‖ (collectively
―Moral Rights‖). To the extent such Moral Rights cannot be assigned under applicable law and to the extent the following is allowed by
the laws in the various countries where Moral Rights exist, I hereby waive such Moral Rights and consent to any action of the Company
that would violate such Moral Rights in the absence of such consent.

5. List of Inventions

I have attached hereto as Exhibit A a complete list of all inventions or improvements to which I claim ownership and that I
desire to remove from the operation of this Agreement, and I acknowledge and agree that such list is complete. If no such list is attached
to this Agreement, I represent that I have no such inventions or improvements at the time of signing this Agreement.

F. Non-Solicitation of Company Employees

During the term of my employment and for one (1) year thereafter, I will not encourage or solicit any employee of the
Company to leave the Company for any reason or to accept employment with any other company. As part of this restriction, I will not
interview or provide any input to any third party regarding any such person during the period in question. However, this obligation shall
not affect any responsibility I may have as an employee of the Company with respect to the bona fide hiring and firing of Company
personnel.

G. Company Authorization for Publication

Prior to submitting or disclosing for possible publication or dissemination outside the Company any material prepared by
me that incorporates information that concerns the Company’s business, I agree to deliver a copy of such material to an officer of the
Company for his or her review. Within twenty (20) days following such submission, the Company agrees to notify me in writing whether
the Company believes such material contains any Proprietary Information or Inventions, and I agree to make such deletions and revisions
as are reasonably requested by the Company to protect its Proprietary Information and Inventions. I further agree to obtain the written
consent of the Company prior to any review of such material by persons outside the Company.

Signature of Employee
H. Duty of Loyalty

I agree that, during my employment with the Company, I will not provide consulting services to or become an employee of,
any other firm or person engaged in a business in any way competitive with the Company, without first informing the Company of the
existence of such proposed relationship and obtaining the prior written consent of my manager and the Human Resource Manager
responsible for the organization in which I work.

I. Former Employer Information

I represent that my performance of all the terms of this Agreement and as an employee of the Company does not and will
not breach any agreement to keep in confidence proprietary information, knowledge or data acquired by me in confidence or in trust prior
to my employment by the Company, and I will not disclose to the Company or induce the Company to use any confidential or prop rietary
information or material belonging to any previous employer or others. I have not entered into and I agree I will not enter into any
agreement, either written or oral, in conflict herewith or in conflict with my employment with the Company. I further agree to conform to
the rules and regulation of the Company.

J. Severability

I agree that if one or more provisions of this Agreement are held to be unenforceable under applicable law, such provisions
shall be excluded from this Agreement and the balance of the Agreement shall be interpreted as if such provision were so excluded and
shall be enforceable in accordance with its terms.

K. Authorization to Notify New Employer

I hereby authorize the Company to notify my new employer about my rights and obligations under this Agreement following
the termination of my employment with the Company.

L. Entire Agreement

This Agreement sets forth the entire agreement and understanding between the Company and my relating to the subject
matter herein and merges all prior discussions between us, including but not limited to any and all statements made by any officer,
employee or representative of the Company regarding the Company’s financial condition or future prospects. I understand and
acknowledge that, except as set forth in this Agreement and in the offer letter from the Company to me, (i) no other representation or
inducement has been made to me, (ii) I have relied on my own judgement and investigation in accepting my employment with the
Company, and (iii) I have not relied on any representation or inducement made by any officer, employee or representative of the
Company. No modification of or amendment to this Agreement nor any waiver of any rights under this Agreement will be effective unless
in a writing signed by the President of the Company and me. I understand and agree that any subsequent change or changes in my
duties, salary or compensation will not affect the validity or scope of this Agreement.

M. Effective Date

This Agreement shall be effective as of the first day of my employment with the Company and shall be binding upon me,
my heirs, executor, assigns and administrators and shall inure to the benefit of the Company, its subsidiaries, successors and assigns.

Signature of Employee
N. Governing Law

Although I may work for the Company outside of India, I understand and agree that this Agreement shall be interpreted and
enforced in accordance with the laws of India.

I recognize that any violation of my obligations described herein can result in disciplinary action, including dismissal from
/Company, and any other appropriate relief for Company including money damages, equitable relief and attorney’s fees as the Company
may deem fit.

I HAVE READ THIS AGREEMENT CAREFULLY AND I UNDERSTAND AND ACCEPT THE OBLIGATIONS WHICH IT IMPOSES UPON
ME WITH OUT RESERVATION. NO PROMISES OR

REPRESENTATIONS HAVE BEEN MADE TO ME TO INDUCE ME TO SIGN THIS AGREEMENT. I SIGN THIS
AGREEMENT VOLUNTARILY AND FREELY.

Date

X
Employee Signature

Employee Name (Please Print)

2 |Page CNXALL/ONB/ART/ONBP/PIAIA/1.0
 EXHIBIT A

1. The following is a complete list of all inventions or improvement relevant to the subject matter of my employment by the Company
that have been made or discovered or conceived or first reduced to practice by me or jointly with others prior to my employment by the
Company that I desire to remove from the operation of the Company’s Proprietary Information and Inventions Agreement:

No Inventions or improvements.

See below: Any and all inventions regarding:

Additional sheets attached.

2. I propose to bring to my employment the following material and documents that I obtained during the period of my prior employment.
These materials and documents are not the property of any third party and are not subject to any restrictions under any non-disclosure
agreement or other agreement limiting their use.

No materials or documents

See below:

X
Employee Signature

Date
 SELF DECLARATION FOR NAME MISMATCH

I DESETTI SIVASAI KUMAR residing at

The name mentioned in my Pan card is

The name in my Passport is

The name in my Aadhaar is

The name in my SSC (10th) Marksheet/Certificate is

The name in my HSC (12th) Marksheet/Certificate is

The name in my Graduation ([Link]/B.A…) Marksheet/ Passing Certificate is

The name in my Post Graduation ([Link]/M.A…) Marksheet/ Passing Certificate is

The name in my Other Educational document (Diploma/Professional Course…) Marksheet/ Passing Certificate is

The name in the Experience/Reliving Letter for

is

I declare that all the above names are one and the same person. I declare that my correct name is

The averments in the declaration mentioned above are true and if found later to be false, the company will have the liberty to
proceed appropriately against the employee for perjury.

Date:

SIGNATURE OF CANDIDATE:
 CRIMINAL BACKGROUND VERIFICATION FORM

Employee Name Emp ID

Photo of the
DOB Contact No.
employee.
Father / Mother /Husband’s Name DESETTI SAMBA SIVA RAO Cross sign
Details required for Criminal Background Verification / Address Verification
the photo.

Please provide following address details:

1) 2 years of Present Address (including Past Address, incase duration at Present Address is less than 2 years)
2) Permanent address.
Please fill all the details correctly & appropriately including Point of reference with their contact details.

Police Duration of stay at the Point of Reference# along with Contact details
Complete Address Details station/ address provided
S. No
with phone number (if any) District / Start Date End Date
State (Approx) (Approx) Name of Address of the Phone
(MM-YY) (MM-YY) Contact contact No.

2 Past** Address 1

3
Past** Address 2

4
Past** Address 3

* Present Address: Address where you are currently staying

** Past Address: Address(es) where you were staying prior to your Present address in last 2 years
***Permanent address: Address where you are permanently residing, irrespective of Present address, and where communications to you
may be sent. This is typically your parent’s residence, or an address in your home town. This can be a rented property also. This may or
may not be the same as your present and past addresses.
# Reference: Could be your Parents, Spouse, Neighbors, Friends, Relatives, Roommate who stayed with you etc. or staying in
close neighborhood Note: All fields are Mandatory as per applicability.
Self-Declaration:
I understand and agree that Concentrix (which includes Concentrix Daksh Services India Private Limited or Concentrix Services India
Private Limited or Concentrix Technologies India Private Limited or Convergys India Services Private Limited as applicable) has required
that I either submit a valid passport to Concentrix or undergo certain background checks (including criminal record verification). As I have
not submitted a valid passport, I understand that I will be required to undergo these background checks and as per the terms and
conditions mentioned in your Appointment letter’

In this connection, I specifically authorize Concentrix to deduct cost up to INR 1500/- of such background checks from my payroll and
shall not raise any claims against Concentrix with respect to the deduction of such amounts."

I hereby, declare that the above-mentioned information provided by me is true to the best of my knowledge & belief.

I understand that the above information furnished by me will be used for conducting Background Verification by the
Organization/Third Party Vendor appointed by Organization. I have no objection to the conduct of such background verification by
any third party/ vendor approved by Concentrix.
I hereby authorize them to undertake verification of my background and criminal records / previous addresses through police/ any other
authorities.

If any of the above-mentioned information is found to be fraudulent or incorrect or negative record/report found during the background
verification, the Company has the right to take appropriate disciplinary action against me, including Termination.
Date Signature of the employee
CNXALL/ONB/ART/ONBP/CBV/1.0
 REQUISITION FOR "CONCENTRIX EMPLOYEE" PHOTO ID BADGE

`TO: Security Control Room Date: 21.03.2022 Version 3.2

EMPLOYEE DETAILS PHOTO

FULL NAME (As Per

WD) EMPLOYEE ID

REASON

DATE OF JOINING

PROCESS

(White Background Passport Size Photo

Only)
PERIOD From / / to / /
* For Fixed Term Hire (FTH) Specify Duration (DD/MM/YYYY)

SIGNATURE OF THE EMPLOYEE

HUMAN RESOURCE (HR) REPRESENTATIVE APPROVAL

*Applicable for New Joinee, Extension and Lost

NAME Nasir Pasha

216102
EMPLOYEE ID

SIGNATURE

PSCA MANAGER (PRIMARY / SECONDARY) APPROVAL AUTHORIZATION TO CARRY RESTRICTED ITEMS

ON THE FLOOR
(Please put tick mark against icons
below)

NAME PEN
EMPLOYEE ID LAPTOP
MOBILE (CAMERA / NON –
CAMERA) STAR (NO
RESTRICTION)
FOR ACCESS REQUEST ONLY DATE OF RECEIPT : / /

BRT REQUEST #
BADGE
CONTROL #
LOCATION /
SITE

Signature :
(ACCESS CONTROL STAFF)
Note:
1. Authorization icons are applicable for Specific Business where employees name is reflected in the authorization list.
2. For 'STAR' category, employee has to obtain necessary approvals from all businesses of location and share with Security
to process the badge.
3. Special Category icons (Star, Pen, Mobile, and Laptop) applies to employee Base location only. For all other building’s
employee may be requested to show his / her name in the authorization list.
4. This form has to be submitted at the respective location Security Control Room. Badge will be delivered within 7 to 10
working days after submission of form.
5. Access to any Project Specific Controlled Area (PSCA) can be requested via PSCA Online Tool as per the process.
6. Please report loss of badge to Security / Control Room (SCR) immediately.
7. If you have lost or misplaced your ID badge, necessary deduction will be done as per policy from your salary through
payroll to process replacement badge.

DESETTI SIVASAI KUMAR

NEW JOINEE YES / NO

LOST
UNUSABLE
22.03.2022
WHEELZ

Vizag
 ONBOARDING CHECKLIST
Name of
DESETTI SIVASAI KUMAR
Candidate:
Pls Note: All documents must be signed by
the employee with Name and Date.
However, Onboarding SPOC need not sign all documents, common sign off on checklist would suffice and
would mean that all document marked on the checklist
have been checked and verified by the HR SPOC
Serial Documents required Onboardi EDC SPOC/Top X SPOC
No. Undergraduate: If the person is undergraduate or pursuing graduation, then ng SPOC
proof required of 12 years of formal education and candidate should be 18
years of age. Yes
NA
1 For Final Year Result Awaited: Proof of 12 years of formal education and 1st
EDUCA & 2nd year mark sheets or consolidated mark sheet for both years with no Yes
TIONAL backlogs. NA
CERTIFI
CATES Graduate: In case of Degree any document issued by the university /
(Self institute / from where the certificate has been issued, needs to certify either Yes NA
Attested scores / grades / "PASS" status with the duration clearly mentioned. The
) same needs to be verified by the Onboarding SPOC for
Internet Mark sheets completion and correctness. No 10th or 12th required.
OR
are also
In case of 3 years (or more) Diploma, he/she needs to provide Diploma
accepted Yes NA
certificate / mark sheets for 3 years or proof of 15 years of formal
(Docume
education. Only 12th class certificate required along with Diploma
nts to be Yes NA Check not to
checked be done by
Education Document with Roll/Registration Number has been attached Yes NA
through EDC
Website, In addition to above any Professional Qualification (Post Graduation Certificate /
if reqd), Provisional Certificate) or any other Professional / Diploma / Degree certification
to be attached if completed / passed
Name of the Company (To be Entered by Onboarding SPOC) - All companies relevant experience in Application Form /
Prospective Employee Detail’s should be mentioned here
(NO ORDER REQUIRED)
2
Company Name 1

Company Name 2

Company Name 3

Company Name 4

Company Name 5

Company Name 6
WORK
EXPERIEN
CE
CERTIFICA Any document issued by the company
with Joining and Relieving dates can
TES (Self
be taken. List of options for both
Attested)
joining and relieving dates are given
(For
below:
employ
ments as
declared
by the
applicant Proof to be collected for DOJ Note: Refer to FAQ for Document Types.
in the
Prospecti 1) Any official document issued by the
ve company on a Letter Head with
Employee Authorized Signatories mentioning DOJ
Detail’s (Pls mention the document name)
/Applicati
on Form)
Experienc
e
Checking

For CL 12 & CL 11: or in case it is not on a Letterhead then it should Yhave signa tures and
guidelines
Experien stamp from a Company Official. Note: Yes
es Yes Yes
ce Yes
documen Refer to FAQ for Document Types. Yes
ts to be
checked
upto
1 year of
employme
nt prior to
joining
Concentrix
 (which iPsronoft to be collected for Last Working Day/Last Day in Organization the Service/Experience Certificate as mentioned above
includes submitted or the last working date is not mentioned clearly in these
Concentri documents - Any one of the following documents Note: Refer to FAQ for
x Daksh Document Types.
Services
India
Private
Limited
or 2) Any official document issued by the company on a Letter Head with
Concentrix Services
Authorized Signatories mentioning LWD / LDO / Date of relieving /
India
or private limited
Concen Contract End Date
(Please mention theisdocument
mentionedname) Yes Yes
trix
Technologies India Note: Refer to FAQ for Document Types. Yes Yes Yes Yes
Private
Limited or
Convergy
s India
Services
Pvt Ltd as
applicable)
.
For CL 10 to CL 5:
up to 3 Other Alternatives for LWD / LDO
years of
employme Y Y Y Y Y  Yes
3) Any Salary Slip of the last 3 months from es es es es es
nt prior to
joining the LWD along with Self Declaration of
Concentrix
1. JAF/Application employment –

form Refer
Y Y Y Y  Yes
/Prospect Artifact
ive Yes es es es es
s OR
Employee Any Bank Statement of the last 3 months
from the LWD / Pass Book entry
Detail’s
would be
the
primary source of mentioning the Name of the Organization/candidate or Employee ID along with Self
checking employees Declaration of employment
experience by the Refer Artifacts for Form
EDC (Name of candidate/Employee ID/Name
team. of Company needs to be highlighted by
2. Experi the SPOC)
ence
documen
ts to be
collected Proof to be collected for (DOJ, LWD / LDO OR BOTH)
and
checked
for the
number
of years
indicated
as
experien
ce in the Form / 4) Email from Last employer confirming DOJ & / OR LWD or email initiated
Application
Prosp by our HR/Recruitment Team to candidate's last employer for confirmation
Em e cptliov ye e e Detail’s,
of his/her DOJ & / OR LWD.
3. In case
OR
C o p y of resignation email mentioning the last working day which is sent
of any
cutting
related to
work
the experienceform
Application on to the relevant people/ department of the concerned company from
official email id with acknowledgment from Company's official ID as
/ " A c c e p te d/R Yes Yes Yes Yes Yes Yes
Prospe
ctive e c e iv e d ".
Employee Detail’s, OR
resulting Copy of resignation email along with
in salary the last working day from personal
change, email ID to official Email ID with
file would acknowledgment from
be sent back to the Company's official ID as "Accepted/Received" along with Any official
recruiter to issue an document issued by the company on a Letter Head with Authorized
addendu Compensation.
m with 4. Any other correction on the

revised
S mentioning DOJ (if DOJ not mentioned
i in the email/artifacts).
g
n 5 ) A n y o ffic ial d o c um en t i s su e d b y the company on a Letter Head with
Auth orize d Si g n a to ries me n t o i n in g DOJ & LW D / LDO / Date of relieving / Contract
a
t
o
r
i
e
s
Application Form / End Date is mentioned (Please mention the document name)
Em PrpolsopyecetiDvetailO
sR
Rehire Check Form Yes Yes
(For Concentrix Rehire Candidate) Yes Yes Yes
can be Note: Refer to FAQ for Document Types. Yes
corrected
and
signed by
the
candidate
&
recruiter
with
recruiters
EMP ID.
Please note: The objective of the exercise is to have proof of employment of the candidate with that
organization clearly indicating the DOJ and LWD/LDO.
1. Therefore any one or combination of the above listed documents must be collected as a proof/artifact for

DOJ or Last Day in organizations.

2. Respective HR onboarding Spoc must check the authenticity/correctness of the document by validating

them against originals

3. Second level of validation will be done by EDC team to ensure complete set of documents have been Check not to
submitted and there is no mismatch of information between various documents submitted. be done by
3 Photographs – 02 Passport Size Photographs of Self (most recent) Yes EDC
4 No Hire University / Company Check conducted Yes
NA
CNXALL/ONB/ART/ONBP/JCL/4.0
 ONBOARDING CHECKLIST

Name of Candidate: DESETTI SIVASAI KUMAR

Serial No. Documents required Onboarding EDC
SPOC SPOC/Top X
SPOC
5
PHOTO Any Photo Id proof issued by Govt Body (Pls mention the document name)  Ye  NA
IDENTIFICATI s
ON PROOF
DOCUMENTS
(Self
Attested)
1) Photo copy of PAN Card / Internet Copy with PAN number
(In case PAN card is not available, then OPTION 2 needs to be filled) No
6 Yes
Note: Pan card copy "Will be Accepted" as a DOB proof but Pan Card Internet Copy "Will
PAN Not Be Accepted" as DOB proof
Details
Any ONE Yes NA
2) PAN Application acknowledgement receipt along with PAN Undertaking
of the 2
options

7 1) Is passport available? (Note: in case the employee is not able to submit, he needs Yes No CL 12 to CL 11:
Passport to be informed of the timeline by when passport has to be submitted as per passport EDC SPOC
(Mandatory process - HR Onboarding SPOC responsible). to check copy
requirement of the
for CL 10 passport, if
and above) "YES" is ticked
Any ONE of in point 1
the 3 No CL 10 and
2) CL 10 and above employees, Passport is a mandatory requirement: - Does the Yes above: EDC
options employee have a valid passport?
In case SPOC to only
passport is check for a
3)  NA
provided, passport or
- If "No" has been selected in the above point, Is the passport application receipt applied for
the same  Ye
submitted by the candidate? OR status, else
can be used s
- Is the passport application status available online?
as DOB employee ID
proof. should not be
created
 Yes  NA
8 Photocopy of Aadhaar Card / E-Aadhaar Copy with number
Mandatory Joining Documents
9 Joining Report  Yes  NA
10 Agreement Regarding Confidential Information, Intellectual Property, and Other Matters  Yes  NA
(NDA)
11 Composite Declaration Form - 11  Yes  NA
12 PF Form 2 (Revised) - 1 Copy (In case of any hiring is not done through One Touch it  Yes  NA
should have 2 copies of PF Form 2)
13 Gratuity form (Form 'F')  Yes  NA
14 Form I (Nomination & Declaration)  Yes  NA
Criminal Background Verification Form (Applicable for CL 12 to CL 11  Yes  NA
15 employee’s not submitting valid copy of Passport) Note: Candidate
should sign the form and photograph.
16 Name mentioned in Application Form / Prospective Employee Detail’s Form should match  Yes  NA
with the Aadhaar Card
Non - Mandatory Joining Documents (if applicable)
ESI (1copy) & one postcard size photographs (HEAD TO TOE), in case require
dependent spouse /children / parents to be covered, then the postcard
17 photograph should be along with them.  Yes  NA
Note: The photograph should cover the ―"Full
Body "‖ preferably with white background Only
Passport Size Photograph required (For
Mumbai,Thane,Pune & Vadodra )
18 Physically challenged (PWD) and Salary equal to or less than Rs. 25000/-; If yes then ESI  Yes  NA
 form to be filled. If No, then please tick NA.
19 Foreign National Proof Document (Work permit \ Visa \ SSN)  Yes  NA
20 Joining Bonus (If Applicable)  Yes  NA Check not to
be done by
EDC
21 PROPRIETARY INFORMATION AND INVENTIONS AGREEMENT  Yes  NA
22 CONFLICT OF INTEREST DISCLOSURE FORM  Yes  NA
23 COEBC-Receipt of Acknowledgement  Yes  NA

Name of Onboarding SPOC: Nasir Pasha

Date (dd/mm/yy):

Employee ID of Onboarding SPOC: 216102 Signature:

Certify that
photocopies
have been
verified with
originals
(Onboarding
SPOC)
CNXALL/ONB/ART/ONBP/JCL/4.0
 TRANSPORT RULES

I, DESETTI SIVASAI KUMAR, agree and acknowledge that I have been provided transport facilities by Concentrix Corporation
(hereinafter, ―Concentrix‖) for commuting to and from the office. I hereby confirm that I have read and understood the below rules
relating to the transport facilities and undertake to follow these rules. In addition, I shall follow all other directives issued by the Company
from time to time with respect to the Company transport facilities. All other applicable rules and regulations of the Company shall
continue to apply to my use of the transport facilities.

I confirm that I shall adhere to all rules applicable to the transport facilities. A current copy of these rules has been reproduced
below.

―As an employee of Concentrix, you are expected to: -

 Be present at the designated place and time for boarding your cab.
 Board and De-Board the cab in a safe manner and only after the vehicle has come to a complete halt.
 In case of ―First Female Boarding and Last Drop‖ (FFBLD) scenarios (i.e. if you are a female employee who is being picked
up first or being dropped last on a route, between 7 p.m. and 7 a.m. (West Region i.e. Pune & Mumbai FFBLD window
timing is 8:30 PM to 7 AM) DO NOT, under any circumstances, board without a male employee / Security guard being
present, demand that a Security Guard be present in the cab. It is a serious violation of Concentrix Policy, it also
jeopardizes employee safety. This rule is valid despite any instructions you may receive from any party, including your
reporting manager.
 Note down and carry with you the Centralized Emergency Helpdesk Contact
Numbers for all the Legacy CNX location:

Sahayata - 1800-123-7752 / 1800-419-0654 (2nd Option)

- Vizag: 9160758892
- Hyderabad: 9515101071
- Chennai: 9790998999
- Bangalore: Millennium Tower, PTP - 9743800076 / Manyata (MTP) - 9901442338 / PSN & BCPV–
9945680680 /Ecospace- 9743800075
- NCR/Chandigarh: 0124-4717444
- Noida: 0120-3817819
- Mumbai: 022-40605777
- Pune: 8308995441
- Kolkata: 9830370700 / 033-66344217

Kindly feed the Toll-Free No. 1800 200 1988 if you are in Pune, NCR/ Chandigarh / Bangalore. Numbers for

all the New CNX location:

Transport Helpline -Toll free no: 1800-208-1000 (Except Hyderabad)

Emergency numbers:

- Hyderabad- 9515101071(emergency & Helpline)

- Bangalore-9739080080
- Gurgaon - 9999256000
- Thane -9833809888
- Pune -9923000770

Release 2.0

Document Owner India SO & Transport Leader

 Always keep the doors of a moving cab locked.
 Always wear seatbelts, especially if you are traveling on the front seat.
 Always treat your driver with respect. Do not be rude to the driver or provide instructions– he is an employee of someone else.
 Confirm the authenticity of the cab before boarding it.
 If you are a Cab Leader (i.e. if you are the first to be picked up or the last to be dropped, ensure that all cab users fill up and sign the
Cab Reporting / Departure Slip. As a Cab Leader do take responsibility for safe conduct of co passengers, especially female
colleagues. At the time of drop Cab Leader needs to make sure that female employee should not be dropped last or picked up first
in absence of security Guard.
 Assist the driver in following traffic rules.
 If the driver engages in rash driving while driving, stop the cab immediately and contact the Centralized Emergency Helpdesk.
 If the driver is feeling sleeping during driving, stop the cab immediately and contact the Centralized Emergency Helpdesk.
 Wear & Display your id card while boarding the cabs.
 Call up Centralized Emergency Helpdesk and your Manager if you notice or are subjected to any suspicious or
inappropriate behavior during the journey.

This would include but is not limited to the following:

✓ Personal / intrusive questions

✓ Questions / comments of sexual nature
✓ Threatening behavior of any sort
✓ Staring/ inappropriate visual or facial behavior
✓ Inappropriate physical contact
✓ Requests for money or financial assistance
✓ Any other behavior that you consider unsafe or that merits the attention of the Transport Department

 If the driver threatens you, report the matter to the Emergency Helpline.
 Keep the FM/ Music at a low volume.
 Cabs will be utilized for official duties only.
 If the driver asks for money, report the matter to the Emergency Helpline.
 Report any service lapse or traffic violation to the Emergency Helpline.
 Don’t board the cab if the driver does not have a visibly seen and valid ID Card, or if you believe that it is another person.
 Don’t delay departure of the cab – it leads to penalty to the driver and to his vendor.
 Don’t get into an argument with the driver / vendor's supervisor. Instead, report the matter to the Transport Executive.
 Don’t take any personal favors from drivers or become familiar with them.
 Don’t display unethical behavior
 Do not indulge in falsification of log sheets
 Don’t consume alcohol or any other contraband substances while traveling in the cab. It is a violation of transport policy as well as the
law.
 Don’t smoke inside the cab –you will be fined. Don’t carry hazardous materials / Unethical substances in the cab. It is a violation of
the law.
 Don’t fall asleep if you are on the front seat.
 Women employees are NOT permitted to sit on the front seat – it is a violation of Company policy.
 Don’t try to drive the cab under any circumstances. It is a violation of the Company Policy.
 Don’t allow non- Concentrix employees to travel in the cab.
 If you carry / wear expensive items while traveling in the cab, you do so at your own risk.

Release 2.0

Document Owner India SO & Transport Leader

 Don’t divulge personal information while traveling in the cab – do NOT reveal your cell number to anyone you do not know.
 Don’t request the driver for a change of route – it is strictly prohibited.
 Don’t ask for unscheduled stops – it has safety implications and is violation of Company policy.
 Do not deviate the cab from the scheduled route – it will result in serious action against defaulters.
 Do not request drivers to pick up or drop from locations other than specified in the routes
 Do not behave or appear in such a manner that encourages an unwarranted approach from the driver or others.
 Do not discuss / disclose any confidential business information.‖
 Employee will login / logout on driver device on their own and where ever applicable will sign the CRS.
 Do not engage yourself with your co passengers for any kind of social/ personal/controversial topics which makes negative
impression and tends to create any unwanted issue. Employees are responsible for the safety of their personal belongings.

I confirm that I have read the above and agree to comply with them. I understand and acknowledge that any breach of these may attract
disciplinary action as the Company deems fit.

Name:

Signature:

Date:

Release 2.0

Document Owner India SO & Transport Leader

 SELF-TRANSPORT UNDERTAKING

DECLARATION FOR NOT AVAILING COMPANY TRANSPORT

I am aware that I may avail of free company-provided transport and security facilities for travel between my residence and workplace,
if I am required to work from office between 7.00 PM and 7.00 AM for any reasons whatsoever.

However, for personal reasons, and on my own volition, I hereby declare that I will not avail company-provided transport but will make
my own arrangements for transport between 7:00 PM and 7:00 AM. (In Maharashtra i.e. Pune & Mumbai timing between 8:30 PM to 7
AM)

I am aware of, and fully understand the risks involved with not using Company-provided transport during the above hours. I have
considered these risks and have taken the decision to make my own transport arrangements, keeping in mind my convenience and
personal preferences.

I understand and acknowledge that I will be responsible for my safety and security once I leave the Company premises and while
commuting to and from office. I am voluntarily making my own transport arrangements and I will be responsible for the consequences
thereof. I understand and acknowledge that Concentrix (which includes Concentrix Daksh Services India Private Limited or Concentrix
Services India Private Limited or Concentrix Technologies India Private Limited or Convergys India Services Private Limited as
applicable) will have no liability whatsoever arising out of this and I waive any claims that I may have against Concentrix in this
respect.

I am aware that I may avail of the transport and security facility provided by Concentrix at any point of time, by suitably notifying the
transport operations team of Concentrix.

Thanking you

Your’s sincerely,

Employee Name:

EMP ID /Applicant ID: 00410040066

Designation: Representative, Operations

Employees’s Signature

Date:

I have read, understood, and acknowledge and agree with the above declaration in its entirety.
Dear Manager,

I am employed with Concentrix Daksh Services India Private Limited.

I will abide by the company policies, processes and guidelines.

However, if I will be part of any internal/domestic inquiry during my tenure in the organization, the investigation team may inspect my
system, mobile details or anything that supports during the investigation to decipher the truth in the interest of company.

I hereby declare that I shall share the required data and details on my own accord and without any pressure from the company.

I have read, understood and acknowledge and agree with the above declaration in its entirety.

Thanking You,

Employee Name: Date :

Signature:
1. I DESETTI SIVASAI KUMAR, working with Concentrix (which includes Concentrix Daksh Services India Private Limited or Concentrix
Services India Private Limited or Concentrix Technologies India Private Limited or Convergys India Services Private Limited as
applicable)), declare and confirm as follows: I understand and agree that, as part of the ongoing attendance process, Concentrix is
authorized to collect my biometric information (fingerprints), for the purposes of verifying and validating my identity and map the same to hours
productivity analysis and reporting. I understand and agree that Biometric Swipe in and Swipe Out data will be used as my attendance input for
Payroll computation and payment.

2. I hereby provide my explicit consent for Concentrix to collect, retain, handle and otherwise process such biometric informati on for
attendance, verification and similar authentication purposes, during the course of my employment with Concentrix.

3. I understand and agree that Concentrix may authorize third parties to collect, store, handle, process, or otherwise use such biometric
information for the purposes contemplated under this consent form (including for any purposes related to, incidental to or necessary to
accomplish such purposes) and has provided me with the necessary information relating to the same. I explicitly consent to Concentrix
disclosing or transferring my biometric information to such third parties, whether located in India or outside India. I understand that Concentrix
shall require such third parties to follow levels of data protection similar to that followed by Concentrix, or as required by applicable law. The
name and address of any such third parties that handle my biometric information shall be provided to me on request.

4. I understand that I may seek to review the biometric information provided by me and retained by Concentrix.

5. I understand that if I have any queries or grievances related to the biometric information provided by me, I may contact my HR partner.

6. I further understand that this authorization and consent is provided solely for the purpose as specified above. I understand that Concentrix
shall treat my biometric information disclosed to it as confidential. Concentrix shall use appropriate security standards to keep my biometric
information confidential.

Date:

Signature of Employee:
 Undertaking

I DESETTI SIVASAI KUMAR, (S/O) (D/O) DESETTI SAMBA SIVA RAO having his/her permanent
residing address at 37-12-64/5/A/SF-201, ANJINADRI ENCLAVE, NGOS COLONY, NG
,VISAKHAPATNAM,Andhra Pradesh,530007, working with CONCENTRIX DAKSH SERVICES INDIA PVT
LTD
[Link]-9-13-45-2/9/4(3), WARD NO-16
7TH FLOOR, SRK DESTINY, VIP ROAD, VIZAG-530003 as Representative, Operations hereby
execute this undertaking in relation to the awareness
session having complete understanding about the Sexual Harassment of Women at Workplace (Prevention,
Prohibition and Redressal) Act (―Act ―), 2013.

I further undertake that I have gone through the complete session and have understood the information provided to
me.

Signed by

Name -

Designation -

Date -

# NAME COMPANY EMPLOYEE SIGNATURE

1.

2.

3.
4.

5.

6.

7.

8.

9.

10.

11.

12.

13.

14.

15.

16.

17.

18.

19.

20.

21.

22.

23.
24.

25.

26.

27.

28.

29.
 # NAME COMPANY EMPLOYEE SIGNATURE

1.

2.

3.

4.

5.

6.

7.

8.

9.

10.

11.

12.

13.

14.

15.

16.

17.

18.

19.

20.

21.
 # NAME COMPANY EMPLOYEE SIGNATURE

22.

23.

24.

25.

26.

27.

# NAME COMPANY EMPLOYEE

SIGNATURE

1.

2.

3.

4.

5.

6.

7.

8.
# NAME COMPANY EMPLOYEE

SIGNATURE

9.

10.

11.

12.

13.

14.

15.

16.

17.

18.

19.

20.

21.

22.

23.

24.

25.

26.

27.

28.
# NAME COMPANY EMPLOYEE

SIGNATURE

29.

30.

31.

32.

33.

34.

35.

36.

37.

38.

39.

40.

41.

42.

43.

44.

45.

46.
# NAME COMPANY EMPLOYEE

SIGNATURE

47.

48.

49.

50.

51.

52.

53.

54.

55.

56.

57.

58.

59.

60.

61.

62.

63.

64.

65.

66.

67.
# NAME COMPANY EMPLOYEE

SIGNATURE

68.

69.

70.

71.

72.

73.

74.

75.

76.

77.

78.

79.

80.

81.

82.

83.

84.

85.

86.

87.

88.

89.

90.
 # NAME COMPANY EMPLOYEE

SIGNATURE

91.

92.

93.

94.

95.

96.

97.

98.

99.

Name of Address of the family member Date of Relationship with

S. No. Address
Name Birth member
(1) (2) (3) (4) (5)

4
[Link] of person making nomination
(in block letters)
 [Link]'s/Husband's Name

[Link] of Birth
[Link]

[Link] Status

[Link] Address

[Link] Address

I hereby nominate the person(s)/cancel the nomination made by me

previously and nominate the person(s) mentioned below to receive any
amount due to me from the employer, in the event to my death.
x
1. Advertisement Number & Sr. No. :

2. Application for the post of :

3. Name of the applicant :

4. Date and place of birth :

5. Age :

Nationality :
6.
7. Marital Status :

8. Whether belongs to SC/ST/OBC :

community (if so, give details and
attach copy of certificate)

9. Religion :
10. Disability :
(attach photocopy of certificate)

11. Permanent address :

12. Address for correspondence :

with telephone/mobile
number and e-mail address

13. Qualifications (beginning with SSC or equivalent. Attach photocopies of all certificates and mark lists of all
semesters/years) :

Examination University/ Subjects Year of %of marks & Class/

Degree/Diploma Institute Passing Grade/distinction
obtained
 14. Other qualification (if any) :

15. Details of projects done( if any) :

16. Details of publications (if any) :

17. Are you employed in a Govt./Semi-Govt./:

Public Sector Undertaking/Autonomous
body? (If yes, you are required to forward
your application through proper channel)

18. Are you under any contractual obligation :

to serve the Govt./Semi-Govt./Public Sector Undertaking/Autonomous
body? If yes, give details.

19. Experience/Details of present and previous employment (attach photocopies of experience certificates) :

Name of Employer Designation of Period of Service Salary

the post held From To

20. Names and addresses of two referees : 1)

2)

21. Have you at any time been called: for interview in the Centre?
If so, give details:

I' hereby declare that the statements made in this application are true, complete and correct to the best of my knowledge and
belief.

Place:

Date: (Signature of the candidate)

Please fill the application form

―Employer‖ Position applying for

PERSONAL DATA
Name (last, first, middle)

Street Address and/or Mailing Address City State Zip

Home Telephone Number Business Telephone Number Cellular Telephone Number

Date you can start work Salary Desired Do you have a High School Diploma or GED?
Yes No
POSITION INFORMATION Check all that you are willing to work
Hours: Full Time Swing
Part Time Days Graveya Status: Regular
Evenin rd Tempora
gs Weekends ry
Are you authorized to work in the U.S. on an unrestricted basis? Yes No

Have you ever been convicted of a felony? (Convictions will not necessarily disqualify an Yes No
applicant for employment.) If yes, explain:
Have you been told the essential functions of the job or have you been viewed a copy of the job description listing the
essential functions of the job? Yes No
Can you perform these essential functions of the job with or without reasonable accommodation? Yes No

QUALIFICATIONS Please list any education or training you feel relates to the position applied for that would help you perform the
work, such as schools, colleges, degrees, vocational or technical programs, and military training.

School Name Degree Address/City/State

School

School

Other

SPECIAL SKILLS List any special skills or experience that you feel would help you in the position that you are applying for (leadership,
organizations/teams, etc.

REFERENCES Please list three professional references not related to you, with full name, address, phone number, and
relationship. If you don’t have three professional references, then list personal, unrelated references.

Name Address/City/State Phone Relationship

 WORK HISTORY Start with your present or most recent employment and work back. Use separate sheet if necessary. (INCLUDE PAID A
UNPAID POSITIONS)
Job Title #1 Start Date (mo/day/yr) End Date (mo/day/yr)

Company Name Supervisor’s Name Phone Number

City State Zip

Duties:

Reason for Leaving Starting Salary Ending Salary

May we contact your present employer? Yes No N/A

Job Title #2 Start Date (mo/day/yr) End Date (mo/day/yr)

Company Name Supervisor’s Name Phone Number

City State Zip

Duties:

Reason for Leaving Starting Salary Ending Salary

Job Title #3 Start Date (mo/day/yr) End Date (mo/day/yr)

Company Name Supervisor’s Name Phone Number

City State Zip

Duties:

Reason for Leaving Starting Salary Ending Salary

Job Title #4 Start Date (mo/day/yr) End Date (mo/day/yr)

Company Name Supervisor’s Name Phone Number

City State Zip

Duties:

Reason for Leaving Starting Salary Ending Salary

Applicant Signature Date

 Affix recent
Post Applied For: -------------------------------------------- Photograph

1. Personal Details

a) Name :

b) Father’s Name/Husband’s Name :

c) Date of Birth :

d) Age as on today :

e) Sex :

f) Marital Status :

g) Category (SC/ST/OBC/GEN) :

h) Nationality :

Af

2. Address for Correspondence / Permanent Address

Address :

Telephone Number

Mobile Number

E-Mail

3. Academic Qualifications

Examination Passed :

Name of Institution / Board :

Year of Passing :

% of Marks :
Driver *
LMV Licence No : Date of expired:
HMV Licence No. : Date of expired:

Stenographer*

Typing
Language
Lower (Yes / No) Higher (Yes / No)
English

Tamil

* Enclose relevant certificates with this application

4. Past Experience:

Organization :

Designation :

Pay Scale :

Period :

Job Description :

Total experience :
 :
Please put your signature
1. NAME OF CANDIDATE: across the photograph.

FIRST NAME:

MIDDLE NAME:

SURNAME:

2. FATHER’S NAME:

3. MOTHER’S NAME:

4) GENDER: MALE FEMALE

5) DATE OF BIRTH (DD/MM/YYYY)

6) AGE (as on 01-01-2017) Years Months Days

7) PERMANENT ADDRESS:

P.O
City

District.

State.

Pin code:
8) ADDRESS FOR CORRESPONDENCE:

P.O
City.

District.

State.

Pin Code

9) MOBILE NUMBER:

10) E- MAIL ID:

11) EDUCATIONAL QUALIFICATIONS.

QUALIFICATION/NAME SUBJECTS/ YEAR OF GRADE /

UNIVERSITY/BOARD SPECIALIZATION
OF COURSE PASSING PERCENTAGE

12) PROFESSIONAL EXPERIENCE:

Employment details (Please add extra sheets if required)

DURATION
SL DESIGNATION ORGANIZATION. Total Job Responsibilities
From To
NO (in months)

Total Experience: (................... yrs................... M........... days)

13) TRAINING AND OTHER COURSES ATTENDED.

DURATION
SL NAME OF TRAINING / OTHER NAME OF INSTITUTE From To Total
NO COURSES ATTENDED

14) LANGUAGE KNOWN: (PLEASE TICK √ )

SL NO LANGUAGE WRITING READING SPEAKING

Declaration:

I hereby declare that all the statements made by me in the application form and information sheet are true and complete
to the best of my knowledge and belief and nothing has been concealed or suppressed. I also understand that in case,
any of my statements is found untrue during any stage of recruitment and thereafter, I shall be disqualified for the post
applied for and I shall be liable for any penal action.

Date: Signature of the Candidate

Place:
 Signature / Left Thumb Impression

1 Full Name (Full expanded name to be mentioned as appearing in proof of identity/date of birth/address documents: initials are not permitted)

Please select title,  as applicable Shri Smt. Kumari M/s

Last Name / Surname

First Name
Middle Name
2 Abbreviations of the above name, as you would like it, to be printed on the PAN card

3 Have you ever been known by any other name?

Yes No (please tick as applicable)

If yes, please give that other name

4 Gender (for Individual applicants only) Male Female Transgender (please tick as applicable)
5 Date of Birth/Incorporation/Agreement/Partnership or Trust Deed/ Formation of Body of individuals or Association of Persons
Day Month Year

6 Details of Parents (applicable only for individual applicants)

Whether mother is a single parent and you wish to apply for PAN by furnishing the name of your mother only?
Yes No (please tick as applicable)
If yes, please fill in mother’s name in the appropriate space provide below.
Father’s Nam e (Manda tory except where mother is a single parent and PAN is applied by furnishing the name of mother only)
Last Name / Surname
First Name
Middle Name
Mother’s Name (optional except where mother is a single parent and PAN is applied by furnishing the name of mother only)
Last Name / Surname
First Name
Middle Name
Select the name of either father or mother which you may like to be printed on PAN card (Select one only)
Father’s name Mother’s name (Please tick as applicable)
(In case no option is provided then PAN card will be issued with father’s name except where mother is a single parent and you wish to apply for PAN
by furnishing name of the mother only)’.
7 Address
Residence Address
Flat / Room / Door / Block No.
Name of Premises / Building / Village
Road / Street / Lane/Post Office
Area / Locality / Taluka/ Sub- Division
Town / City / District
State / Union Territory Pincode / Zip code Country Name
 Office Address
Name of office
Flat / Room / Door / Block No.
Name of Premises / Building / Village
Road / Street / Lane/Post Office
Area / Locality / Taluka/ Sub- Division
Town / City / District
State / Union Territory Pincode / Zip code Country Name

8 Address for Communication Residence Office (Please tick as applicable)

9 Telephone Number & Email ID details
Country code Area/STD Code Telephone / Mobile number

Email ID
10 Status of applicant
Please select status,  as applicable Government
Individual Hindu undivided family Company Partnership Firm Association of Persons
Trusts Body of Individuals Local Authority Artificial Juridical Persons Limited Liability Partnership
11 Registration Number (for company, firms, LLPs etc.)

12 In case of a person, who is required to quote Aadhaar number or the Enrolment ID of Aadhaar application form as per section 139 AA
Please mention your AADHAAR number (if allotted)
If AADHAAR number is not allotted, please mention the enrolment ID of Aadhaar application form

Name as per AADHAAR letter or card or as per the Enrolment ID of Aadhaar application form

13 Source of Income Please select,  as applicable

Salary Capital Gains

Income from Business / Profession Business/Profession code [For Code: Refer instructions] Income from Other sources
Income from House property No income
14 Representative Assessee (RA)
Full name, address of the Representative Assessee, who is assessible under the Income Tax Act in respect of the person, whose particulars have
been given in the column 1-13.
Full Name (Full expanded name : initials are not permitted)

Please select title,  as applicable Shri Smt. Kumari M/s

Last Name / Surname
First Name
Middle Name
Address
Flat / Room / Door / Block No.
Name of Premises / Building / Village
Road / Street / Lane/Post Office
Area / Locality / Taluka/ Sub- Division
Town / City / District
State / Union Territory Pincode

15 Documents submitted as Proof of Identity (POI), Proof of Address (POA) and Proof of Date of Birth (POB)
I/We have enclosed as proof of identity,
as proof of address and as proof of date of birth.
[Please refer to the instructions (as specified in Rule 114 of I.T. Rules, 1962) for list of mandatory certified documents to be submitted as applicable]
[Annexure A, Annexure B & Annexure C are to be used wherever applicable]
16 I/We , the applicant, in the capacity of
do hereby declare that what is stated above is true to the best of my/our information and belief.

Place :
D D M M Y Y Y Y
Date :
Item
Item Details Guidelines for filling the form
No.
1 Please select appropriate title.
Do not use abbreviations in the First and the Last name/Surname. written as :

Last
Name/Surname

First Name

Middle Name

F
FATHER NAME

Last
Name/Surname

First Name

Middle Name

MOTHER NAME

Last
Name/Surname

First Name

Middle Name

MANAGER NAME

Last
Name/Surname

First Name

Middle Name

TEAM LEADER NAME

HR NAME

Last
Name/Surname

First Name

Middle Name

PROJECT HEAD NAME

Last
Name/Surname
 First Name

Middle Name

ASSISTANT MANAGER
Last
Name/Surname

First Name

Middle Name

2 FLOOR SECRETARY NAME

Last
Name/Surname

First Name

Middle Name

15 Proof of Identity, It is mandatory to attach proof of identity, proof of address and proof of date of birth with PAN application.
Proof of Address Documents should be in the name of applicant. List of documents which will serve as proof of
and Proof of Date identity, address and date of birth for each status of applicant is as given below:
of Birth
documents

(Signature of Candidate)
Code Business/ Profession Code Business/ Profession
01 Medical Profession and Business 11
02 Engineering 12
03 Architecture 13

04 Chartered Accountant/ Accountancy 14

05 Interior Decoration 15

06 Technical Consultancy 16

Plying Taxis, Lorries, Trucks, Buses or other

07 Company Secretary 17
Commercial Vehicles
08 Legal Practitioner and Solicitors 18 Ownership of Horses or Jockeys
09 Government Contractors 19 Cinema Halls and Other Theatres
10 Insurance Agency 20 Others
 1 Name (in Block Letters) :

2 Father’s/Husband’s Name :

3 Date of birth :

4 Sex :

5 Marital Status :

6 Account No. (PF/EPS Number) :

7 Address (Residential) :

Name and Address of the Nominees Date of Birth Total amount of If the nominee is minor, name and
nominee/nominees relationship share relationship and address of the
with the o guardian who may receive the amount
member f during the minority of nominee
accumulations
is Provident
Fund to be paid
to each
nominee (%)
(1) (2) (3) (4) (5)

1 * Certified that I have no family as defined in para 2(g) of the Employees’ Provident Funds Scheme, 1952, and should I
acquire a family hereafter, the above nomination should be deemed as cancelled.
2 * Certified that my father/mother is/are dependent upon me.
3. * Strike out whichever is not applicable.
X----------------------------------------------------------------
Signature or thumb impression of the
 In sum, in 2024 we did what we said we would. We expanded our offerings in adjacent solutions
and digital IT services to position Concentrix as a leader in integrated business solutions. We
accelerated our market leadership position by expanding our global-scale delivery and driving
new client innovation through GenAI leadership. And we delivered strong financial results while
enhancing shareholder value.
CHALLENGING THE STATUS QUO, ACCELERATING GROWTH
We are confident we have built the right platform to accelerate our growth and leadership and
remain steadfast in our commitment to visibility, velocity, and value.
In 2025, we believe we will continue to deliver shareholder value by:
1) Growing our revenue, earnings and free cash flow by providing trusted, intelligent
business solutions that power our clients’ success;
2) Expanding our share repurchase program above prior year’s level;
3) Reducing our debt and maintaining investment grade principles; and
4) Supporting our dividend, which we have increased each year since inception.

These priorities are reflected in our executive long-term incentive compensation program for
2025, which includes a focus on driving earnings per share growth and significant total
shareholder return to align with the interests and expectations of our long-term investors.
At the same time, we will continue to challenge the status quo and seek new ways to innovate
and drive value for our 2,000 clients who rely on Concentrix every day to power a world that works.
We win when our clients win.
As we look forward to the years ahead, I am excited about where we are on our journey. I thank
our dedicated game-changers for their tenacity, hard work, and commitment to excellence and
innovation. I also thank our clients for their trust, our talented Board of Directors for their support
and mentorship, and you, our stockholders, for your continued confidence in Concentrix.

Sincerely,

(Concentrix
Corporation)

1
Pro forma constant currency revenue growth, non-GAAP operating income, adjusted EBITDA, and adjusted free cash flow
are non-GAAP financial measures. See pages 38-41 and 46 of the accompanying Annual Report on Form 10-K and our
Current Report on Form 8-K filed with the Securities and Exchange Commission on January 15, 2025, for more information,
including reconciliations to the most directly comparable GAAP measures.
Results of Operations – Fiscal Years Ended November 30, 2024 and 2023

Fiscal Years Ended November

30, 2024 2023
(in thousands)
Revenue
Cost of revenue
Gross profit
Selling, general and administrative expenses
Operating income
Interest expense and finance charges, net
Other expense (income), net
Income before income taxes
Provision for income taxes
Net income before non-controlling interest

Revenue

Fiscal Years Ended November 30, Percent Change

2024 2023 2024 to 2023
(in thousands)
Industry vertical:
Technology and consumer electronics
Retail, travel and e-commerce
Communications and media
Banking, financial services and insurance
Healthcare
Other
Total

We generate revenue by delivering our technology and services to our clients categorized in the above
primary industry verticals. Our solutions focus on customer engagement, process optimization, and back-office
automation.
Our revenue increased 35.2% in fiscal year 2024, primarily as a result of the Webhelp Combination. These
increases were partially offset by an unfavorable translation effect of foreign currencies of $66.3 million, or 0.9%.
The unfavorable foreign currency translation effect on revenue was primarily due to the weakening of the
Argentine peso and Japanese yen against the U.S. dollar. If the Webhelp Combination had occurred at the
beginning of fiscal year 2023, our revenue would have increased by 1.4% in fiscal year 2024.
Revenue in our technology and consumer electronics vertical increased over the prior year due to
contributions as a result of the Webhelp Combination and increases in volumes from several social media and
internet-related service clients. Revenue in our retail, travel and e-commerce vertical increased over the prior
year, and most significantly in comparison to all verticals, due to the Webhelp Combination generating larger
increases in revenue along with increased volumes from several of our largest retail and e-commerce and
travel and tourism clients.
Revenue in our communications and media vertical increased over the prior year primarily due to contributions
as a result of the Webhelp Combination partially offset by decreases in volumes from several clients. Revenue
from clients in the banking, financial services and insurance vertical increased over the prior year primarily due
to contributions as a result of the Webhelp Combination. Revenue in our healthcare vertical increased over the
prior year primarily due to contributions as a result of the Webhelp Combination partially offset by decreases in
volumes
 from several healthcare clients. Revenue in our other vertical increased over the prior year primarily due to
contributions from the Webhelp Combination.

Cost of Revenue, Gross Profit and Gross Margin Percentage

Fiscal Years Ended November 30, Percent
Change 2024 2023 2024 to 2023
($ in thousands)
Cost of revenue
Gross profit
Gross margin %

Cost of revenue consists primarily of personnel costs. Gross margins can be impacted by resource
location, client mix and pricing, additional lead time for programs to be fully scalable, and transition and initial
set-up costs.
Our cost of revenue increased by 36.0% in fiscal year 2024, compared to fiscal year 2023, primarily due to
the increase in our revenue and personnel costs related to staff supporting acquired operations. These increases
were partially offset by a $137.3 million, or 3.0%, reduction in the cost of revenue due to foreign currency
translation. The foreign currency impacts on our cost of revenue were caused primarily by the weakening of the
Argentine peso, Egyptian pound, and Philippine peso against the U.S. dollar. If the Webhelp Combination had
occurred at the beginning of fiscal year 2023, our cost of revenue would have increased by 1.9% in fiscal year
2024.
Our gross profit increased by 33.8% in fiscal year 2024, compared to fiscal year 2023, primarily due to the
increase in revenue and contributions from acquired operations and a net favorable foreign currency impact of
$71.0 million. Our gross margin percentage decreased from 36.2% in fiscal year 2023 to 35.9% in fiscal year
2024 and was affected by the mix of geographies where our services were delivered.

Selling, General and Administrative Expenses

Fiscal Years Ended November 30, Percent
Change 2024 2023 2024 to 2023
($ in thousands)
Selling, general and administrative expenses $ 2,852,500 $ 1,916,608 48.8 %
Percentage of revenue 29.7 % 26.9 %

Our selling, general and administrative expenses consist primarily of support personnel costs such as
salaries, commissions, bonuses, employee benefits and share-based compensation costs. Selling, general and
administrative expenses also include the cost of our global delivery facilities, utility expenses, hardware and
software costs related to our technology infrastructure, legal and professional fees, depreciation on our
technology and facility equipment, amortization of intangible assets resulting from acquisitions, marketing
expenses, and acquisition-related and integration expenses.
Our selling, general and administrative expenses increased by 48.8% in fiscal year 2024, compared to
fiscal year 2023, primarily due to incremental expenses associated with acquired operations, increases in
expenses to support our revenue growth, an increase in amortization expense of $244.1 million primarily
associated with the intangible assets recognized in the Webhelp Combination, an increase in acquisition-
related and integration expenses of $85.4 million primarily related to the Webhelp Combination, and an
increase in share-based compensation expense of $33.4 million. These increases were partially offset by a
$28.9 million reduction in selling, general and administrative expenses due to foreign currency translation. As a
percentage of revenue, selling, general and administrative expenses increased from 26.9% for fiscal year 2023 to
29.7% for fiscal year 2024 due to the net effect of the changes described above.
Operating Income
Fiscal Years Ended November 30, Percent Change
2024 2023 2024 to 2023
($ in
thousands)
Operating income
Operating margin

Our operating income decreased during fiscal year 2024, compared to fiscal year 2023, primarily due to
the increase in selling, general and administrative expenses partially offset by the increase in gross profit.
Our operating margin decreased during fiscal year 2024, compared to fiscal year 2023, due to the decrease
in gross margin percentage and the increase in selling, general and administrative expenses as a percentage of
revenue.

Interest Expense and Finance Charges, Net

Fiscal Years Ended November 30, Percent Change
2024 2023 2024 to 2023
($ in
thousands)
Interest expense and finance charges, net
Percentage of revenue

Amounts recorded in interest expense and finance charges, net consist primarily of interest expense on
our senior notes issued in August 2023, interest expense on term loan borrowings under our senior credit
facility, interest expense on borrowings under our accounts receivable securitization facility (the ―Securitization
Facility‖), interest expense on the promissory note issued by us to certain Sellers in connection with the Webhelp
Combination (the ―Sellers' Note‖), and financing expenses incurred in fiscal year 2023 associated with our
commitment letter dated March 29, 2023 (the ―Bridge Commitment Letter,‖ and the commitments pursuant to the
Bridge Commitment Letter, the ―Bridge Facility‖), entered into in connection with the Webhelp Combination.
The increase in interest expense and finance charges, net during fiscal year 2024 compared to fiscal year
2023, was primarily due to an increase in interest expense on our senior notes of $98.3 million over the prior
year, an increase in interest expense, including imputed interest, associated with the Sellers' Note of $26.3
million over the prior year, and a decrease in interest income related to the senior notes proceeds of $7.8 million
incurred in the prior year period that did not recur in fiscal year 2024. The senior notes and the Sellers' Note were
outstanding for only a portion of the fiscal year 2023. These changes were partially offset by a decrease in
Bridge Facility financing fees and credit facility amendment fees of $22.5 million incurred in fiscal year 2023 that
did not recur.

Other Expense (Income), Net

Fiscal Years Ended November 30, Percent
Change 2024 2023 2024 to 2023
($ in thousands)
Other expense (income), net
Percentage of revenue

Amounts recorded as other expense (income), net primarily include foreign currency transaction gains and
losses other than cash flow hedges, investment gains and losses, the non-service component of pension costs,
other non-operating gains and losses, and changes in acquisition contingent consideration related to the
Webhelp Combination.
Other expense (income), net in fiscal year 2024 was $24.7 million of income compared to $52.1 million of
expense in fiscal year 2023. The change in other expense (income), net over the prior fiscal year period was
due to income of $29.3 million during fiscal year 2024 related to the change in acquisition contingent
consideration associated with the Webhelp Combination in comparison to an expense of $15.7 million in the
prior fiscal year,
 resulting in a year over year change of $44.9 million. The remainder of the change resulted from a loss on
derivative contracts entered into in connection with the Webhelp Combination in fiscal year 2023 of $14.6
million that did not recur and net foreign currency gains on a year-over-year basis.

Provision for Income Taxes

Fiscal Years Ended November 30, Percent
Change 2024 2023 2024 to 2023
($ in thousands)
Provision for income taxes
Percentage of income before income taxes

Our provision for income taxes consists of our current and deferred tax expense resulting from our income
earned in domestic and international jurisdictions.
Our provision for income taxes and effective tax rate decreased for fiscal year 2024, compared to fiscal
year 2023, primarily due to the geographical mix of income and higher use of net operating loss
carryforwards, and a
$12.3 million net tax benefit related to certain legal entity restructuring activities.
See Note 13—Income Taxes to the consolidated financial statements included elsewhere in this Annual
Report on Form 10-K for further details.

Certain Non-GAAP Financial Information

In addition to disclosing financial results that are determined in accordance with GAAP, we also disclose
certain non-GAAP financial information, including:
• Non-GAAP operating income, which is operating income, adjusted to exclude acquisition-related
and integration expenses, including related restructuring costs, step-up depreciation, amortization
of intangible assets and share-based compensation.
• Non-GAAP operating margin, which is non-GAAP operating income, as defined above,
divided by revenue.
• Adjusted earnings before interest, taxes, depreciation, and amortization, or adjusted EBITDA,
which is non-GAAP operating income, as defined above, plus depreciation (exclusive of step-
up depreciation).
• Adjusted EBITDA margin, which is adjusted EBITDA, as defined above, divided by revenue.
• Non-GAAP net income, which is net income excluding the tax effected impact of acquisition-related
and integration expenses, including related restructuring costs, step-up depreciation, amortization
of intangible assets, share-based compensation, imputed interest related to the Sellers' Note,
change in acquisition contingent consideration and foreign currency losses (gains), net. Non-GAAP
net income also excludes the income tax effect of certain legal entity restructuring activity.
• Free cash flow, which is cash flows from operating activities less capital expenditures, and
adjusted free cash flow, which is free cash flow excluding the effect of changes in the outstanding
factoring balance. We believe that free cash flow is a meaningful measure of cash flows since
capital expenditures are a necessary component of ongoing operations. We believe that adjusted
free cash flow is a meaningful measure of cash flows because it removes the effect of factoring
which changes the timing of the receipt of cash for certain receivables. However, free cash flow and
adjusted cash flow have limitations because they do not represent the residual cash flow available
for discretionary expenditures. For example, free cash flow and adjusted free cash flow do not
incorporate payments for business acquisitions.
• Non-GAAP diluted earnings per common share (―EPS‖), which is diluted EPS excluding the per
share, tax effected impact of acquisition-related and integration expenses, including related
restructuring costs, step- up depreciation, amortization of intangible assets, share-based
compensation, imputed interest related to the Sellers' Note, change in acquisition contingent
consideration and foreign currency losses (gains), net. Non- GAAP EPS also excludes the per
share income tax effect of certain legal entity restructuring activity. Non-
 GAAP EPS excludes net income attributable to participating securities, and the per share, tax-
effected impact of adjustments to net income described above that are attributable to common
shareholders.
We believe that providing this additional information is useful to the reader to better assess and understand
our base operating performance, especially when comparing results with previous periods and for planning
and forecasting in future periods, primarily because management typically monitors the business adjusted for
these items in addition to GAAP results. Management also uses these non-GAAP measures to establish
operational goals and, in some cases, for measuring performance for compensation purposes. These non-
GAAP financial measures exclude amortization of intangible assets. Our acquisition activities have resulted in
the recognition of intangible assets, which consist primarily of customer relationships, technology, and trade
names. Finite-lived intangible assets are amortized over their estimated useful lives and are tested for
impairment when events indicate that the carrying value may not be recoverable. The amortization of intangible
assets is reflected in our statements of operations.
Although intangible assets contribute to our revenue generation, the amortization of intangible assets does
not directly relate to the services performed for our clients. Additionally, intangible asset amortization expense
typically fluctuates based on the size and timing of our acquisition activity. Accordingly, we believe excluding
the amortization of intangible assets, along with the other non-GAAP adjustments, which neither relate to the
ordinary course of our business nor reflect our underlying business performance, enhances our and our
investors' ability to compare our past financial performance with its current performance and to analyze
underlying business performance and trends. Intangible asset amortization excluded from the related non-GAAP
financial measure represents the entire amount recorded within our GAAP financial statements, and the revenue
generated by the associated intangible assets has not been excluded from the related non-GAAP financial
measure. Intangible asset amortization is excluded from the related non-GAAP financial measure because the
amortization, unlike the related revenue, is not affected by operations of any particular period unless an
intangible asset becomes impaired or the estimated useful life of an intangible asset is revised. These non-GAAP
financial measures also exclude share-based compensation expense. Given the subjective assumptions and
the variety of award types that companies can use when calculating share-based compensation expense,
management believes this additional information allows investors to make additional comparisons between our
operating results and those of our peers. As these non-GAAP financial measures are not calculated in
accordance with GAAP, they may not necessarily be comparable to similarly titled measures employed by
other companies. These non-GAAP financial measures should not be considered in isolation or as a substitute
for the comparable GAAP measures and should be used as a complement to, and in conjunction with, data
presented in accordance with GAAP.
 Fiscal Years Ended November 30,
2024 2023
($ in thousands except per share amounts)
Operating income
Acquisition-related and integration expenses
Step-up depreciation
Amortization of intangibles
Share-based compensation
Non-GAAP operating income

Net income
Interest expense and finance charges, net
Provision for income taxes
Other expense (income), net
Acquisition-related and integration expenses
Step-up depreciation
Amortization of intangibles
Share-based compensation
Depreciation (exclusive of step-up depreciation)
Adjusted EBITDA

Operating margin
Non-GAAP operating margin
Adjusted EBITDA margin

Net income
Acquisition-related and integration expenses
Step-up depreciation

charges, net (1)

Acquisition-related expenses included in other expense (income),
net (1)
Imputed interest related to Sellers' Note included in interest
expense and finance charges, net
Change in acquisition contingent consideration included in other
expense (income), net
Foreign currency losses (gains), net (2)
Amortization of intangibles
Share-based compensation
Income taxes related to the above (3)
Income tax effect of legal entity restructuring
Non-GAAP net income
 Fiscal Years Ended November 30,
2024 2023
Diluted earnings per common share (―EPS‖)
Acquisition-related and integration expenses
Step-up depreciation
Acquisition-related expenses included in interest expense and
finance charges, net (1)
Acquisition-related expenses included in other expense (income),
net (1)
Imputed interest related to Sellers' Note included in interest expense
and finance charges, net
Change in acquisition contingent consideration included in other
expense (income), net
Foreign currency losses (gains), net (2)
Amortization of intangibles
Share-based compensation
Income taxes related to the above (3)
Income tax effect of legal entity restructuring
Non-GAAP Diluted EPS
(1)
Included in these amounts are a) Bridge Facility financing fees and b) losses associated with non-designated call option
contracts put in place to hedge foreign exchange movements in connection with the Webhelp Combination that are
included within interest expense and finance charges, net and other expense (income), net, respectively, in the
consolidated statement of operations.
(2)
Foreign currency losses (gains), net are included in other expense (income), net and primarily consist of gains and losses
recognized on the revaluation and settlement of foreign currency transactions and realized and unrealized gains and
losses on derivative contracts that do not qualify for hedge accounting. The reported amounts for non-GAAP net income
and non-GAAP EPS for the fiscal year ended November 30, 2024 and 2023 include adjustments to exclude these
foreign currency losses (gains), net.
(3)
The tax effect of taxable and deductible non-GAAP adjustments was calculated using the tax deductible portion of the
expenses and applying the entity specific, statutory tax rates applicable to each item during the respective fiscal
years.

Client Concentration
In fiscal years 2024 and 2023, no client accounted for more than 10% of our consolidated revenue.

Liquidity and Capital Resources

Our primary uses of cash are working capital, capital expenditures to expand our delivery footprint and
enhance our technology solutions, debt repayments, acquisitions, and acquisition-related and integration
expenses, including in connection with our combination with Webhelp in September 2023. Our financing needs
for these uses of cash have been a combination of operating cash flows and third-party debt arrangements. Our
working capital needs are primarily to finance accounts receivable. When our revenue is increasing, our net
investment in working capital typically increases. Conversely, when revenue is decreasing, our net investment in
working capital typically decreases. To increase our market share and better serve our clients, we may further
expand our operations through investments or acquisitions. We expect that such expansion would require an
initial investment in working capital, personnel, facilities, and operations. These investments or acquisitions would
likely be funded primarily by our existing cash and cash equivalents, available liquidity, including capacity on
our debt arrangements, or the issuance of securities. We funded the Webhelp Combination through (i) proceeds
from our August 2023 offering and sale of senior notes, (ii) term loan borrowings under our senior credit facility,
and (iii) cash on hand.
In September 2021, considering our strong free cash flow, low leverage and adequate liquidity to support
capital return to stockholders while maintaining flexibility to pursue acquisitions, our board of directors authorized a
share repurchase program. Under the share repurchase program, the board of directors authorized the repurchase
of up to
$500 million of our common stock from time to time as market and business conditions warrant, including through
open market purchases or Rule 10b5-1 trading plans. The share repurchase program has no termination date
and may be suspended or discontinued at any time. During the fiscal years ended November 30, 2024 and
2023, we repurchased 2,200,819 and 709,438 shares, respectively, of our common stock under the share
repurchase program
 for approximately $136.1 million and $64.0 million, respectively, in the aggregate. At November 30, 2024,
approximately $154.0 million remained available for share repurchases under the existing authorization from
our board of directors.
During December 2024, we repurchased 150,563 shares of our common stock under the share
repurchase program for an aggregate purchase price of $6.5 million.
In January 2025, our board of directors extended our share repurchase program by authorizing an increase of
the amount remaining for share repurchases under the existing share repurchase authorization to $600 million.
During fiscal years 2024 and 2023, we paid the following dividends per share approved by our board of
directors:

Announcement Date Record Date Per Share Dividend Amount Payment Date
January 19, 2023 January 30, 2023
March 29, 2023 April 28, 2023
June 28, 2023 July 28, 2023
September 27, 2023 October 27, 2023
January 24, 2024 February 5, 2024
March 26, 2024 April 26, 2024
June 26, 2024 July 26, 2024
September 25, 2024 October 25, 2024

Cash Flows – Fiscal Years Ended November 30, 2024 and 2023
The following summarizes our cash flows for the fiscal years ended November 30, 2024 and 2023, as
reported in our consolidated statement of cash flows in the accompanying consolidated financial statements.

Fiscal Years Ended November

30, 2024 2023
($ in thousands)
Net cash provided by operating activities
Net cash used in investing activities
Net cash provided by (used in) financing activities
Effect of exchange rate changes on cash, cash equivalents and
restricted cash
Net increase (decrease) in cash, cash equivalents and restricted cash
Cash, cash equivalents and restricted cash at beginning of year
Cash, cash equivalents and restricted cash at end of year

Free Cash Flow and Adjusted Free Cash Flow (non-GAAP measures)
Fiscal Years Ended November
30, 2024 2023
($ in thousands)
Net cash provided by operating activities
Purchases of property and equipment
Free cash flow (a non-GAAP measure)
Change in outstanding factoring balances
Adjusted free cash flow (a non-GAAP measure)
 CONCENTRIX CORPORATION
CONSOLIDATED BALANCE SHEETS
(currency and share amounts in thousands, except par value)

November 30, 2024 November 30, 2023

ASSETS
Current assets:
Cash and cash equivalents
Accounts receivable, net
Other current assets
Total current assets
Property and equipment, net
Goodwill
Intangible assets, net
Deferred tax assets
Other assets
Total assets $

LIABILITIES AND EQUITY

Current liabilities:
Accounts payable
Current portion of long-term debt
Accrued compensation and benefits
Other accrued liabilities
Income taxes payable
Total current liabilities
Long-term debt, net
Other long-term liabilities
Deferred tax liabilities
Total liabilities
Commitments and contingencies (Note 14)
Stockholders' equity:
Preferred stock, $0.0001 par value, 10,000 shares authorized and no shares issued
and outstanding as of November 30, 2024 and 2023, respectively — —
Common stock, $0.0001 par value, 250,000 shares authorized; 68,849 and 67,883
shares issued as of November 30, 2024 and 2023, respectively, and 64,238 and
65,734 shares
outstanding as of November 30, 2024 and 2023, respectively
Additional paid-in capital
Treasury stock, 4,611 and 2,149 shares as of November 30, 2024 and 2023,
respectively
Retained earnings
Accumulated other comprehensive loss
Total stockholders' equity
Total liabilities and stockholders' equity

The accompanying notes are an integral part of these consolidated financial statements.
 CONCENTRIX CORPORATION
CONSOLIDATED STATEMENTS OF OPERATIONS
(currency and share amounts in thousands, except per share amounts)

Fiscal Years Ended November 30,

2024 2023 2022
Revenue
Cost of revenue
Gross profit
Selling, general and administrative expenses
Operating income
Interest expense and finance charges, net
Other expense (income), net
Income before income taxes
Provision for income taxes
Net income before non-controlling interest
Less: Net income attributable to non-controlling interest
Net income attributable to Concentrix Corporation

Earnings per common share:

Basic
Diluted

Basic
Diluted

The accompanying notes are an integral part of these consolidated financial statements.
 CONCENTRIX CORPORATION
CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME
(currency in thousands)

Fiscal Years Ended November 30,

2024 2023 2022
Net income before non-controlling interest
Other comprehensive income (loss):
Unrealized gains (losses) of defined benefit plans, net of taxes of
$(2,078),
$(894), and $(4,329) for fiscal years ended November 30, 2024, 2023
and 2022, respectively
Unrealized gains (losses) on hedges during the period, net of taxes of
$9,514,
$(4,938), and $15,427 for fiscal years ended November 30, 2024, 2023
and 2022, respectively
Reclassification of net losses on hedges to net income, net of taxes of
$(1,230), $(4,594), and $(9,276) for fiscal years ended November 30,
2024, 2023 and 2022, respectively
Total change in unrealized gains (losses) on hedges, net of taxes
Foreign currency translation adjustments for fiscal years ended
November 30, 2024, 2023 and 2022
Other comprehensive income (loss)
Comprehensive income
Less: Comprehensive income attributable to non-controlling interest
Comprehensive income attributable to Concentrix Corporation

The accompanying notes are an integral part of these consolidated financial statements.
 CONCENTRIX CORPORATION
CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY
(currency and share amounts in thousands)

Concentrix Corporation Stockholders’ Equity

Common Stock Treasury stock
Redeemabl Accumulated
e non- Additional other
controlling paid- Retaine comprehensive
interest Shares Amount in Shares Amount d income (loss) Total
capita earning
l s
Balances, November 30, 2021 $ — 51,594 $ 5 $ 2,355,767 333 $ (57,486) $ 392,495 $ (70,526) $ 2,620,255
Other comprehensive loss
Equity awards issued as acquisition
purchase consideration
Acquisition of non-controlling interest
in subsidiary
Net income attributable to
non- controlling interest
Purchase of non-controlling interest in
subsidiary
Share-based compensation activity
Repurchase of common stock for tax
withholdings on equity awards
Repurchase of common stock
Dividends
Net income
Balances, November 30, 2022
Other comprehensive income
Common stock issued as acquisition
purchase consideration
Share-based compensation activity
Repurchase of common stock for tax
withholdings on equity awards
Repurchase of common stock
Dividends
Net income
Balances, November 30, 2023
Other comprehensive loss
Share-based compensation activity
Repurchase of common stock for tax
withholdings on equity awards
Repurchase of common stock
Dividends
Net income
Balances, November 30, 2024

The accompanying notes are an integral part of these consolidated financial statements.
 CONCENTRIX CORPORATION
CONSOLIDATED STATEMENTS OF CASH FLOWS
(currency in thousands)
Fiscal Years Ended November 30,
2024 2023 2022
Cash flows from operating activities:
Net income before non-controlling interest
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation
Amortization
Non-cash share-based compensation
Provision for doubtful accounts
Deferred income taxes
Unrealized foreign exchange loss
Loss on call options
Amortization of debt discount and issuance costs
Pension and other post-retirement benefit costs
Pension and other post-retirement plan contributions
Change in acquisition contingent consideration
Other
Changes in operating assets and liabilities:
Accounts receivable, net
Accounts payable
Other operating assets and liabilities
Net cash provided by operating activities

Purchases of property and equipment

Premiums paid for call options
Acquisitions of business, net of cash and restricted cash acquired
Other investments
Net cash used in investing activities

Proceeds from the Restated Credit Facility - Term Loan

Repayments of the Restated Credit Facility - Term Loan
Proceeds from the Prior Credit Facility - Term Loan
Repayments of the Prior Credit Facility - Term Loan
Repayments of the original credit facility - original term loan
Proceeds from the Securitization Facility
Repayments of the Securitization Facility
Proceeds from the issuance of Senior Notes
Other debt proceeds
Other debt repayments
Cash paid for debt issuance costs
Purchase of non-controlling interest in subsidiary
Cash paid for acquired earnout liabilities
Proceeds from exercise of stock options
Repurchase of common stock for tax withholdings on equity awards
Repurchase of common stock
Dividends paid
Change in funds held for clients
Net cash provided by (used in) financing activities
Effect of exchange rate changes on cash, cash equivalents and restricted cash
Net increase (decrease) in cash, cash equivalents and restricted cash
Cash, cash equivalents and restricted cash at beginning of year
Cash, cash equivalents and restricted cash at end of year

The accompanying notes are an integral part of these consolidated financial statements.
 CONCENTRIX CORPORATION
CONSOLIDATED STATEMENTS OF CASH FLOWS

(currency in thousands)
Fiscal Years Ended November 30,
2024 2023 2022
Supplemental disclosures of cash flow information:
Interest paid on borrowings
Income taxes paid
Supplemental disclosure of non-cash investing activities:
Accrued costs for property and equipment purchases

The accompanying notes are an integral part of these consolidated financial statements.
 The following table summarizes the final fair values of the assets acquired and liabilities assumed as of the
acquisition date:

As of
July 20, 2022
Assets acquired:
Cash and cash equivalents
Accounts receivable
Property and equipment
Operating lease right-of-use assets
Identifiable intangible assets
Goodwill
Net deferred tax assets
Other assets
Total assets acquired

Liabilities assumed:
Accounts payable and accrued liabilities
Operating lease liabilities
Total liabilities assumed

Total consideration transferred $

The purchase price allocation includes $40,200 of acquired identifiable intangible assets, all of which
have finite lives. The fair value of the identifiable intangible assets has been estimated using the income
approach through a discounted cash flow analysis of certain cash flow projections. The intangible assets are
being amortized over their estimated useful lives on either a straight-line basis or an accelerated method that
reflects the economic benefit of the asset. The determination of the useful lives is based upon various industry
studies, historical acquisition experience, economic factors, and future forecasted cash flows of the Company
following the acquisition of ServiceSource. During the measurement period included in the fiscal year ended
November 30, 2023, measurement period adjustments were recorded to finalize net deferred tax assets at the
acquired value as disclosed in the table above, resulting in a corresponding decrease to goodwill.

The amounts allocated to intangible assets are as

follows:
Gross Carrying Weighted-Average Acceleratio
Amount Useful Life n
Method
Customer relationships
Technology
Trade name
Total $ 40,200

Acquisition-related and integration expenses

In connection with the Webhelp Combination and the acquisitions of PK and ServiceSource, the Company
incurred $156,771, $71,336, and $33,763 of acquisition-related and integration expenses for the fiscal years
ended 2024, 2023 and 2022, respectively. These expenses primarily include severance and employee-related
costs, legal and professional services, cash-settled awards, retention payments and costs associated with
facilities consolidation, including lease terminations to integrate the businesses. These acquisition-related and
integration expenses were recorded within selling, general and administrative expenses in the consolidated
statement of operations.
 NOTE 4—SHARE-BASED COMPENSATION:
In November 2020, TD SYNNEX Corporation (―TD SYNNEX‖), as the former sole stockholder of Concentrix,
approved the Concentrix Corporation 2020 Stock Incentive Plan (the ―Concentrix Stock Incentive Plan‖) and the
Concentrix Corporation 2020 Employee Stock Purchase Plan (the ―Concentrix ESPP‖), each to be effective upon
completion of Concentrix' spin-off from TD SYNNEX, which occurred on December 1, 2020. 4,000 shares of
Concentrix common stock were reserved for issuance under the Concentrix Stock Incentive Plan, and 1,000
shares of Concentrix common stock were authorized for issuance under the Concentrix ESPP. In December
2021, 2022 and 2023, respectively, 523, 520, and 664 additional shares of Concentrix common stock were
reserved for issuance under the Concentrix Stock Incentive Plan resulting from an automatic annual increase
pursuant to the terms of the plan (the ―Evergreen Provision‖).
On October 28, 2024, the stockholders of Concentrix approved the Concentrix Corporation Amended and
Restated 2020 Stock Incentive Plan (the ―2020 Plan‖) at a Special Meeting of Stockholders that (i) increased
the number of authorized shares thereunder by 3,000 shares and (ii) removed the Evergreen Provision,
among other amendments. The 2020 Plan was previously approved by the Company's board of directors.
The Company recorded share-based compensation expense in the consolidated statements of operations
for fiscal years 2024, 2023 and 2022 as follows:

Fiscal Years Ended November 30,

2024 2023 2022
Total share-based compensation
Tax benefit recorded in the provision for income taxes
Effect on net income

Share-based compensation expense is included in selling, general and administrative expenses in the
consolidated statements of operations.

Employee Stock Options

The Company uses the Black-Scholes valuation model to estimate the fair value of stock options. The
Black- Scholes option-pricing model was developed for use in estimating the fair value of short-lived exchange
traded options that have no vesting restrictions and are fully transferable. In addition, option-pricing models
require the input of subjective assumptions, including the option's expected life and the price volatility of the
underlying stock. The stock options have ten-year terms and vesting terms of five years.
 A summary of the changes in the employee stock options during fiscal years 2022, 2023, and 2024 is
presented below:

Options Outstanding
Weighted-
Number of average
shares (in exercise
thousands) price per share
Balance as of November 30, 2021
Options granted
(1)
Options issued in conversion of certain vested PK stock options
Options exercised
Balance as of November 30, 2022
Options granted
Options exercised
Options cancelled
Balance as of November 30, 2023
Options granted
Options exercised
Balance as of November 30, 2024
(1) Amounts represent the issuance of vested Concentrix stock options that were issued in conversion of certain vested PK
stock options that were assumed by Concentrix pursuant to the merger agreement with PK.

As of November 30, 2024, 238 options were outstanding with a weighted-average life of 3.79 years and an
aggregate pre-tax intrinsic value of $483. As of November 30, 2024, 233 options were vested and exercisable
with a weighted-average life of 3.74 years, a weighted-average exercise price of $55.89 per share, and an
aggregate pre-tax intrinsic value of $483.
As of November 30, 2024, the unamortized share-based compensation expense related to unvested stock
options under the Concentrix Stock Incentive Plan was $178, which will be recognized over an estimated
weighted-average amortization period of 0.85 years.

Restricted Stock Awards, Restricted Stock Units and Performance-Based Restricted Stock Units
The fair value of restricted stock awards and restricted stock units granted under the Concentrix Stock
Incentive Plan in fiscal years 2024, 2023 and 2022 were determined based on the trading price of Concentrix
common stock on the date of grant. The awards are expensed on a straight line basis over the vesting term,
typically three or four years. The holders of restricted stock awards are entitled to the same voting, dividend and
other rights as holders of Concentrix common stock.
In fiscal years 2024, 2023 and 2022, the Company granted performance-based restricted stock units to the
Company's senior executive team. The performance-based restricted stock units will vest, if at all, upon the
achievement of certain annual financial targets during the three-year periods ending November 30, 2026,
November 30, 2025 and November 30, 2024, respectively.
In April 2024, the Company granted performance-based restricted stock units under the Concentrix Stock
Incentive Plan. The performance-based restricted stock units will vest, if at all, upon the achievement of
certain financial targets during the three-year period ending November 30, 2026.
 A summary of the changes in the non-vested restricted stock awards, restricted stock units, and
performance- based stock units during fiscal years 2022, 2023, and 2024, including the conversion of former
parent awards and stock units previously discussed, is presented below:

Weighted-
average, grant-
Number of date
shares (in fair value per
thousands) share
Non-vested as of November 30, 2021
Awards granted
Units granted (1)
Awards and units vested
Awards and units cancelled/forfeited
Non-vested as of November 30, 2022
Awards granted
Units granted (1)
(2)
Performance-based units vested in excess of target
Awards and units vested
Awards and units cancelled/forfeited
Non-vested as of November 30, 2023
Awards granted
Units granted (1)
Awards and units vested
Awards and units cancelled/forfeited
Non-vested as of November 30, 2024

(1) For performance-based restricted stock units, the target number of shares that can be awarded upon full vesting of the grants is included.
(2) Amounts represent performance-based awards that vested in excess of the target number of shares for the fiscal year 2021
performance- based grants.

As of November 30, 2024, there was $227,830 of total unamortized share-based compensation expense
related to non-vested restricted stock awards, restricted stock units and performance-based restricted stock
units granted under the Concentrix Stock Incentive Plan. That cost is expected to be recognized over an
estimated weighted- average amortization period of 2.25 years.
NOTE 5—BALANCE SHEET COMPONENTS:
Cash, cash equivalents and restricted cash:
The following table provides a reconciliation of cash, cash equivalents and restricted cash reported within the
consolidated balance sheets that sum to the total of the same amounts shown in the consolidated statements of
cash flows:

As of November 30,
2024 2023
Cash and cash equivalents
Restricted cash included in other current assets
Cash, cash equivalents and restricted cash

Restricted cash balances relate primarily to funds held for clients, restrictions placed on cash deposits by
banks as collateral for the issuance of bank guarantees and the terms of a government grant, and letters of credit
for leases. Of the restricted cash balance, $179,949 and $218,228 related to funds held for clients as of
November 30, 2024 and 2023, respectively. The Company has a corresponding current liability recorded in other
accrued liabilities on the consolidated balance sheet related to these funds.
Accounts receivable, net:
Accounts receivable, net is comprised of the following as of November 30, 2024 and 2023:

As of November 30,
2024 2023
Billed accounts receivable
Unbilled accounts receivable
Less: Allowance for doubtful accounts
Accounts receivable, net

Allowance for doubtful trade receivables:

Presented below is a progression of the allowance for doubtful trade receivables:

Fiscal Years Ended November 30,

2024 2023 2022

Balance at beginning of period
Net additions (reductions)
Write-offs and reclassifications
Balance at end of period

Property and equipment, net:

The following table summarizes the carrying amounts and related accumulated depreciation for property and
equipment as of November 30, 2024 and 2023:

As of November 30,
2024 2023
Land
Equipment, computers and software
Furniture and fixtures
Buildings, building improvements and leasehold improvements
Construction-in-progress
Total property and equipment, gross
Less: Accumulated depreciation
Property and equipment, net

Shown below are the countries where 10% or more and other significant concentrations of the Company's
property and equipment, net are located as of November 30, 2024 and 2023:

As of November 30,
2024 2023
Property and equipment, net:
United States
Philippines
France
India
Others
Total
Accumulated other comprehensive income (loss):
The components of accumulated other comprehensive income (loss) (―AOCI‖), net of taxes, were as follows:

Unrecognized Unrealized gains Foreign currency

gains (losses) (losses) translation
on
defined benefit on adjustment and
plan, net hedges, net of other,
of taxes taxes net of taxes Total
Balance, November 30, 2022
Other comprehensive income (loss) before
reclassification
Reclassification of losses from other
comprehensive income (loss)
Balance, November 30, 2023
Other comprehensive income (loss) before
reclassification
Reclassification of losses from other
comprehensive income (loss)
Balance, November 30, 2024

Refer to Note 7—Derivative Instruments for the location of gains and losses on cash flow hedges
reclassified from other comprehensive income (loss) to the consolidated statements of operations.
Reclassifications of amortization of actuarial (gains) losses of defined benefit plans is recorded in ―Other
expense (income), net‖ in the consolidated statement of operations.
NOTE 6—GOODWILL AND INTANGIBLE ASSETS:
Goodwill
The Company tests goodwill for impairment annually as of the fourth quarter of its fiscal year and at other
times if events have occurred or circumstances exist that indicate the carrying value of goodwill may no longer be
recoverable. Goodwill impairment testing is performed at the reporting unit level. Based on the current year
assessment, the Company concluded that no impairment charges were necessary for the Company's
reporting unit. The Company has not recorded any impairment charges related to goodwill during the three-year
period ended November 30, 2024.

Below is a progression of goodwill for fiscal years 2024 and 2023:

Fiscal Years Ended November 30,

2024 2023
Balance, beginning of year
Acquisitions
Acquisition measurement period adjustments
Foreign currency translation
Other Intangible Assets
The Company's other intangible assets, primarily acquired through business combinations, are subject to
amortization and are evaluated periodically if events or circumstances indicate a possible inability to recover their
carrying amounts. No impairment charges were recognized in any period presented. As of November 30, 2024
and 2023, the Company's other intangible assets consisted of the following:

As of November 30, 2024 As of November 30, 2023

Gross Accumulate Net Gross Accumulate Net
amount d amount amount d amount
s amortizatio s s amortizatio s
n n
Customer relationships
Technology
Trade names
Non-compete agreements

Amortization expense for intangible assets was $458,925, $214,832, and $162,673 for the fiscal years
ended November 30, 2024, 2023 and 2022, respectively, and the related estimated expense for the five
subsequent fiscal years and thereafter is as follows:
Amortization
Fiscal Years Ending November 30,
2025
2026
2027
2028
2029
Thereafter
Total

The remaining weighted average amortization period for customer relationships and other intangible assets is
approximately 13 years.
NOTE 7—DERIVATIVE INSTRUMENTS:
In the ordinary course of business, the Company is exposed to foreign currency risk and credit risk. The
Company enters into transactions, and owns monetary assets and liabilities, that are denominated in currencies
other than the legal entity's functional currency. The Company may enter into forward contracts, option contracts,
or other derivative instruments to offset a portion of the risk on expected future cash flows, earnings, net
investments in certain non-U.S. legal entities and certain existing assets and liabilities. However, the Company
may choose not to hedge certain exposures for a variety of reasons including, but not limited to, accounting
considerations and the economic cost of hedging particular exposures. There can be no assurance the hedges will
offset more than a portion of the financial impact resulting from movements in foreign currency exchange or
interest rates. Generally, the Company does not use derivative instruments to cover equity risk and credit risk.
The Company's hedging program is not used for trading or speculative purposes.
All derivatives are recognized on the consolidated balance sheets at their fair values. Changes in the fair
value of derivatives are recorded in the consolidated statements of operations, or as a component of AOCI in
the consolidated balance sheets, as discussed below.

Cash Flow Hedges

To mitigate the impact on gross margins from fluctuations in foreign currency exchange rates, certain of
the Company's legal entities with functional currencies that are not U.S. dollars may hedge a portion of
forecasted revenue or costs not denominated in the entities' functional currencies. These instruments mature
at various dates through November 2026. Gains and losses on cash flow hedges are recorded in AOCI until
the hedged item is
 recognized in earnings. Deferred gains and losses associated with cash flow hedges of foreign currency revenue
are recognized as a component of ―Revenue‖ in the same period as the related revenue is recognized, and
deferred gains and losses related to cash flow hedges of foreign currency costs are recognized as a component
of ―Cost of revenue‖ or ―Selling, general and administrative expenses‖ in the same period as the related costs are
recognized. Derivative instruments designated as cash flow hedges must be de-designated as hedges when it is
probable the forecasted hedged transaction will not occur in the initially identified time period or within a
subsequent two-month time period. Deferred gains and losses in AOCI associated with such derivative
instruments are reclassified into earnings in the period of de-designation. Any subsequent changes in fair value
of such derivative instruments are recorded in earnings unless they are re-designated as hedges of other
transactions.

Non-Designated Derivatives
The Company uses short-term forward contracts to offset the foreign exchange risk of assets and liabilities
denominated in currencies other than the functional currencies of the Company's legal entities that own the assets
or liabilities. These contracts, which are not designated as hedging instruments, mature or settle within twelve
months. Derivatives that are not designated as hedging instruments are adjusted to fair value through earnings in
the financial statement line item to which the derivative relates.
During the second quarter of 2023, the Company entered into short-term foreign exchange forward call
option contracts to offset the foreign exchange risk associated with the cash payment required to be made in
euros upon the closing of the Webhelp Combination. These derivatives were not designated as hedging
instruments and were adjusted to fair value through earnings and included in other expense (income), net in
the consolidated statement of operations. These derivatives were settled subsequent to the Webhelp
Combination.

Cross-currency interest rate swaps

In connection with the closing of the Webhelp Combination, the Company entered into cross-currency swap
arrangements with certain financial institutions for a total notional amount of $500,000 of the Company's senior
notes. In addition to aligning the currency of a portion of the Company's interest payments to the Company's euro-
denominated cash flows, the arrangements, together with intercompany loans and additional intercompany cross-
currency interest rate swap arrangements described below, effectively converted $250,000 aggregate principal
amount of the Company's 6.650% Senior Notes due 2026 and $250,000 aggregate principal amount of the
Company's 6.660% Senior Notes due 2028 into synthetic fixed euro-based debt at weighted average interest rates
of 5.12% and 5.18%, respectively.
Concurrent with entering into the cross-currency interest rate swaps with certain financial institutions,
Marnix SAS, a wholly owned subsidiary of Concentrix, entered into corresponding U.S. dollar denominated
intercompany loan agreements with certain other subsidiaries of Concentrix with identical terms and notional
amounts as the underlying $500,000 U.S. dollar denominated senior notes, with reciprocal cross-currency
interest rate swaps.
The cross-currency interest rate swaps are designated as fair value hedges.
Fair Values of Derivative Instruments in the Consolidated Balance Sheets
The fair values of the Company's derivative instruments are disclosed in Note 8—Fair Value Measurements and
summarized in the table below:

Value as of
November 30, November 30,
Balance Sheet Line Item 2024 2023
Derivative instruments not designated as hedging instruments:
Foreign exchange forward contracts (notional value)
Other current assets
Other accrued liabilities
Derivative instruments designated as fair value hedges:
Cross-currency interest rate swaps (notional value)
Other long-term liabilities
Derivative instruments designated as cash flow hedges:
Foreign exchange forward contracts (notional value)
Other current assets and other assets
Other accrued liabilities and other long-term liabilities

Volume of activity
The notional amounts of foreign exchange forward contracts represent the gross amounts of foreign
currency, including, principally, the Philippine peso, the Indian rupee, and the euro, that will be bought or sold
at maturity. The notional amounts for outstanding derivative instruments provide one measure of the
transaction volume outstanding and do not represent the amount of the Company's exposure to credit or
market loss. The Company's exposure to credit loss and market risk will vary over time as currency exchange
rates change.
The Effect of Derivative Instruments on AOCI and the Consolidated Statements of Operations
The following table shows the gains and losses, before taxes, of the Company's derivative instruments
designated as cash flow hedges and not designated as hedging instruments in other comprehensive income
(―OCI‖), and the consolidated statements of operations for the periods presented:

Fiscal Years Ended November 30,

Location of gain (loss) in
statement of operations 2024 2023 2022
Derivative instruments designated
as
cash flow and fair value hedges:
(Losses) gains recognized in OCI:
Foreign exchange forward contracts
Cross-currency interest rate swaps
Total

(Losses) gains reclassified from AOCI

into income:
Foreign exchange forward contracts
Gain reclassified from AOCI into
income Revenue for services $ — $ 222 $ —
(Loss) gain reclassified from Cost of revenue for
AOCI into income services
(Loss) gain reclassified from Selling, general and
AOCI into income administrative expenses
Total

Derivative instruments not

designated
as hedging instruments:
Gain (loss) recognized from foreign Other expense
exchange forward contracts, net(1) (income), net
Loss recognized from foreign Other expense (income),
exchange call options contracts, net net
Total

(1) The gains and losses largely offset the currency gains and losses that resulted from changes in the assets and liabilities
denominated in nonfunctional currencies.

There were no material gain or loss amounts excluded from the assessment of effectiveness. Existing net
losses in AOCI that are expected to be reclassified into earnings in the normal course of business within the
next twelve months are $17,016.

Offsetting of Derivatives
In the consolidated balance sheets, the Company does not offset derivative assets against liabilities in
master netting arrangements.
Credit exposure for derivative financial instruments is limited to the amounts, if any, by which the
counterparties' obligations under the contracts exceed the Company's obligations to the counterparties. The
Company manages the potential risk of credit losses by selecting counterparties from a limited group of
financial institutions with high credit standing.
NOTE 8—FAIR VALUE MEASUREMENTS:
The Company's fair value measurements are classified and disclosed in one of the following three
categories: Level 1: Unadjusted quoted prices in active markets that are accessible at the measurement
date for identical,
unrestricted assets or liabilities;
Level 2: Quoted prices in markets that are not active, or inputs which are observable, either directly or
indirectly, for substantially the full term of the asset or liability; and
Level 3: Prices or valuation techniques that require inputs that are both significant to the fair value
measurement and unobservable (i.e., supported by little or no market activity).
The following table summarizes the valuation of the Company's investments and financial instruments that are
measured at fair value on a recurring basis:

As of November 30, 2024 As of November 30, 2023

Fair value measurement category Fair value measurement category
Total Level 1 Level 2 Level 3 Total Level 1 Level 2 Level 3
Assets measured at
fair value:
Cash equivalents
Foreign government bond — — — — — —
Forward foreign currency
exchange contracts
Liabilities measured at
fair value:
Forward foreign currency
exchange contracts
Cross-currency interest rate
swaps
Acquisition contingent
consideration
Liabilities measured at
other than fair value:
Long term debt (senior
notes)
Fair value
Carrying amount

The Company's cash equivalents consist primarily of highly liquid investments in money market funds and
term deposits with maturity periods of three months or less. The carrying values of cash equivalents
approximate fair value since they are near their maturity. Investment in foreign government bond classified as
an available-for-sale debt security is recorded at fair value based on quoted market prices. The fair values of
forward exchange contracts are measured based on the foreign currency spot and forward rates. Fair values
of long-term foreign currency exchange contracts are measured using valuations based upon quoted prices for
similar assets and liabilities in active markets and are valued by reference to similar financial instruments,
adjusted for terms specific to the contracts. The fair values of the cross-currency interest rate swaps are
determined using a market approach that is based on observable inputs other than quoted market prices,
including contract terms, interest rates, currency rates, and other market factors. The estimated fair value of the
acquisition contingent consideration entered into in connection with the Webhelp Combination was determined
using a Monte-Carlo simulation model. The inputs include the closing price of Concentrix common stock as of
the reporting period end date, Concentrix-specific historical equity volatility, and the risk-free rate.
The effect of nonperformance risk on the fair value of derivative instruments was not material
as of November 30, 2024 and 2023.
 The carrying values of term deposits with maturities less than one year, accounts receivable and accounts
payable approximate fair value due to their short maturities and interest rates that are variable in nature. The
carrying values of the outstanding balance on the term loan under the Company's senior credit facility and the
outstanding balance on the Company's Securitization Facility approximate their fair values since they bear interest
rates that are similar to existing market rates. The fair values of the 2026 Notes, 2028 Notes, and 2033 Notes
(as defined in Note 9) are based on quoted prices in active markets and are classified within Level 2 of the fair
value hierarchy. The Company does not adjust the quoted market prices for such financial instruments.
During fiscal years 2024, 2023 and 2022, there were no transfers between the fair value measurement
category levels.
NOTE 9—BORROWINGS:
Borrowings consist of the following:

As of November 30,
2024 2023
Other loans
Current portion of long-term debt

6.650% Senior Notes due 2026

6.600% Senior Notes due 2028
6.850% Senior Notes due 2033
Credit Facility - Term Loan component
Securitization Facility
Sellers' Note
Other loans
Long-term debt, before unamortized debt discount and issuance costs
Less: unamortized debt discount and issuance costs
Long-term debt, net

Senior Notes
On August 2, 2023, the Company issued and sold (i) $800,000 aggregate principal amount of 6.650%
Senior Notes due 2026 (the ―2026 Notes‖), (ii) $800,000 aggregate principal amount of 6.600% Senior Notes
due 2028 (the ―2028 Notes‖) and (iii) $550,000 aggregate principal amount of 6.850% Senior Notes due 2033
(the ―2033 Notes‖ and, together with the 2026 Notes and 2028 Notes, the ―Senior Notes‖). The Senior Notes
were sold in a registered public offering pursuant to the Company's Registration Statement on Form S-3, which
became effective upon filing, and a Prospectus Supplement dated July 19, 2023, to a Prospectus dated July 17,
2023.
The Senior Notes were issued pursuant to, and are governed by, an indenture, dated as of August 2, 2023
(the ―Base Indenture‖), between Concentrix and U.S. Bank Trust Company, National Association, as trustee (the
―Trustee‖), as supplemented by a first supplemental indenture dated as of August 2, 2023 between Concentrix
and the Trustee relating to the 2026 Notes, a second supplemental indenture dated as of August 2, 2023 between
Concentrix and the Trustee relating to the 2028 Notes, and a third supplemental indenture dated as of August
2, 2023 between Concentrix and the Trustee relating to the 2033 Notes (such supplemental indentures,
together with the Base Indenture, the ―Indenture‖). The Indenture contains customary covenants and restrictions,
including covenants that limit Concentrix Corporation's and certain of its subsidiaries' ability to create or incur
liens on shares of stock of certain subsidiaries or on principal properties, engage in sale/leaseback transactions
or, with respect to Concentrix Corporation, consolidate or merge with, or sell or lease substantially all its assets to,
another person. The Indenture also provides for customary events of default.
The Company incurred debt discount and issuance costs of approximately $19,300 associated with the
issuance of the Senior Notes during the fiscal year ended November 30, 2023, which costs are being amortized
through the applicable maturity dates of the Senior Notes.
Restated Credit Facility
On April 21, 2023, the Company entered into an Amendment and Restatement Agreement (the ―Amendment
Agreement‖) with the lenders party thereto, JPMorgan Chase Bank, N.A. and Bank of America, N.A., to amend and
restate the Company's Prior Credit Facility (as amended and restated, the ―Restated Credit Facility‖).
The Restated Credit Facility provides for the extension of a senior unsecured revolving credit facility not to
exceed an aggregate principal amount of $1,042,500. The Restated Credit Facility also provides for a senior
unsecured term loan facility in an aggregate principal amount not to exceed approximately $2,144,700 (the
―Term Loan‖), of which $1,850,000 was incurred upon the amendment and approximately $294,702 was
drawn on a delayed draw basis on the Closing Date. Aggregate borrowing capacity under the Restated Credit
Facility may be increased by up to an additional $500,000 by increasing the amount of the revolving credit
facility or by incurring additional term loans, in each case subject to the satisfaction of certain conditions set
forth in the Restated Credit Facility, including the receipt of additional commitments for such increase.
As of November 30, 2023, the outstanding principal balance on the Term Loan was $1,950,000 due to
principal payments made subsequent to the Closing Date. During fiscal year 2024, the Company voluntarily
prepaid $450,000 of the principal balance on the Term Loan, without penalty, resulting in an outstanding
balance at November 30, 2024 of $1,500,000.
The maturity date of the Restated Credit Facility is December 27, 2026, subject, in the case of the revolving
credit facility, to two one-year extensions upon the Company's prior notice to the lenders and the agreement of
the lenders to extend such maturity date. Due to the voluntary prepayments previously described, no principal
payment is required until the outstanding principal amount is due in full on the maturity date.
Borrowings under the Restated Credit Facility bear interest, in the case of SOFR rate loans, at a per annum
rate equal to the applicable SOFR rate (but not less than 0.0%), plus an applicable margin, which ranges from
1.125% to 2.000%, based on the credit ratings of the Company's senior unsecured non-credit enhanced long-
term indebtedness for borrowed money plus a credit spread adjustment to the SOFR rate of 0.10%.
Borrowings under the Restated Credit Facility that are base rate loans bear interest at a per annum rate (but
not less than 1.0%) equal to (i) the greatest of (A) the Prime Rate (as defined in the Restated Credit Facility) in
effect on such day, (B) the NYFRB Rate (as defined in the Restated Credit Facility) in effect on such day plus ½
of 1.0%, and (C) the adjusted one-month term SOFR rate plus 1.0% per annum, plus (ii) an applicable margin,
which ranges from 0.125% to 1.000%, based on the credit ratings of the Company's senior unsecured non-credit
enhanced long-term indebtedness for borrowed money.
The Restated Credit Facility contains certain loan covenants that are customary for credit facilities of this
type and that restrict the ability of Concentrix Corporation and its subsidiaries to take certain actions, including
the creation of liens, mergers or consolidations, changes to the nature of their business, and, solely with respect
to subsidiaries of Concentrix Corporation, incurrence of indebtedness. In addition, the Restated Credit Facility
contains financial covenants that require the Company to maintain at the end of each fiscal quarter, (i) a
consolidated leverage ratio (as defined in the Restated Credit Facility) not to exceed 3.75 to 1.0 (or for certain
periods following certain qualified acquisitions, including the Webhelp Combination, 4.25 to 1.0) and (ii) a
consolidated interest coverage ratio (as defined in the Restated Credit Facility) equal to or greater than 3.00 to
1.0. The Restated Credit Facility also contains various customary events of default, including payment defaults,
defaults under certain other indebtedness, and a change of control of Concentrix Corporation.
None of Concentrix' subsidiaries guarantees the obligations under the Restated Credit Facility.
Prior to entering into the Amendment Agreement, obligations under the Company's Prior Credit Facility were
secured by substantially all of the assets of Concentrix Corporation and certain of its U.S. subsidiaries and were
guaranteed by certain of its U.S. subsidiaries. Borrowings under the Prior Credit Facility bore interest, in the case
of term or daily SOFR loans, at a per annum rate equal to the applicable SOFR rate (but not less than 0.0%),
plus an adjustment of between 0.10% and 0.25% depending on the interest period of each SOFR loan, plus an
applicable margin, which ranged from 1.25% to 2.00%, based on the Company's consolidated leverage ratio.
Borrowings under the Prior Credit Facility that were base rate loans bore interest at a per annum rate equal to (i)
the greatest of (a) the Federal Funds Rate in effect on such day plus ½ of 1.00%, (b) the rate of interest last
publicly announced by Bank of America as its ―prime rate‖ and (c) the term SOFR rate plus 1.00%, plus (ii) an
applicable margin, which ranged
 from 0.25% to 1.00%, based on the Company's consolidated leverage ratio. From August 31, 2022 through the
date of the Amendment Agreement, the outstanding principal of the term loans under the Prior Credit Facility
was payable in quarterly installments of $26,250.
During fiscal year 2023, the Company voluntarily prepaid $25,000 of the principal balance on the term
loans under the Prior Credit Facility, without penalty.
As of November 30, 2024 and 2023, no amounts were outstanding under the Company's revolving credit
facility.

Securitization Facility
On April 25, 2024, the Company entered into an amendment to the Securitization Facility to (i) increase
the commitment of the lenders to provide available borrowings from up to $500,000 to up to $600,000, (ii)
extend the termination date of the Securitization Facility from July 5, 2024 to April 24, 2026, and (iii) amend
the interest rate margins, such that borrowings under the Securitization Facility that are funded by certain
lenders through such lenders' issuance of commercial paper bear interest at the applicable commercial paper
rate plus a spread of 0.80% and, otherwise, at a bank rate that includes a per annum rate equal to the
applicable SOFR rate (subject to a SOFR related adjustment of 0.10%), plus a spread of 0.90%.
Under the Securitization Facility, Concentrix Corporation and certain of its subsidiaries (the ―Originators‖)
sell or otherwise transfer all of their accounts receivable to a special purpose bankruptcy-remote subsidiary of
the Company (the ―Borrower‖) that grants a security interest in the receivables to the lenders in exchange for
available borrowings of up to $600,000. The amount received under the Securitization Facility is recorded as
debt on the Company's consolidated balance sheets. Borrowing availability under the Securitization Facility may
be limited by the Company's accounts receivable balances, changes in the credit ratings of the clients
comprising the receivables, client concentration levels in the receivables, and certain characteristics of the
accounts receivable being transferred (including factors tracking performance of the accounts receivable over
time).
The Securitization Facility contains various affirmative and negative covenants, including a consolidated
leverage ratio covenant that is consistent with the Restated Credit Facility and customary events of default,
including payment defaults, defaults under certain other indebtedness, a change in control of Concentrix
Corporation, and certain events negatively affecting the overall credit quality of the transferred accounts
receivable.
The Borrower's sole business consists of the purchase or acceptance through capital contributions of the
receivables and related security from the Originators and the subsequent retransfer of or granting of a security
interest in such receivables and related security to the administrative agent under the Securitization Facility for
the benefit of the lenders. The Borrower is a separate legal entity with its own separate creditors who will be
entitled, upon its liquidation, to be satisfied out of the Borrower's assets prior to any assets or value in the
Borrower becoming available to the Borrower's equity holders, and the assets of the Borrower are not
available to pay creditors of the Company and its subsidiaries.
On January 14, 2025, the Company entered into an amendment to the Securitization Facility to increase the
commitment of the lenders to provide available borrowings from up to $600,000 to up to $700,000 and extend the
termination date of the Securitization Facility from April 24, 2026 to January 14, 2027.

Sellers’ Note
On September 25, 2023, as part of the consideration for the Webhelp Combination, Concentrix
Corporation issued the Sellers' Note in the aggregate principal amount of €700,000 to certain Sellers. The
stated rate of interest associated with the Sellers' Note is two percent (2.00%) per annum, which is below the
Company's expected borrowing rate. As a result, the Company discounted the Sellers' Note by €31,500 using
an approximate 4.36% imputed annual interest rate. This discounting resulted in an initial value of €668,500 or
$711,830. The discounted value is being amortized into interest expense over the two-year term. All stated
principal and accrued interest will be due and payable on September 25, 2025.
Amounts outstanding under the Sellers' Note have been classified as long-term debt within the consolidated
balance sheet based on the Company's ability and intent to refinance on a long-term basis as of November 30,
2024.
Covenant compliance
As of November 30, 2024 and 2023, Concentrix was in compliance with all covenants for the above
arrangements.

Future principal payments

As of November 30, 2024, future principal payments under the above loans for the subsequent fiscal
years are as follows:

Amount
Fiscal Years Ending November 30,
2025
2026
2027
2028
2029
Thereafter
Total

NOTE 10—REVENUE:
Disaggregated revenue
In the following tables, the Company's revenue is disaggregated by primary industry verticals and geographic
locations:

Fiscal Years Ended November 30,

2024 2023 2022
Industry vertical:
Technology and consumer electronics
Retail, travel and e-commerce
Communications and media
Banking, financial services and insurance
Healthcare
Other
Total
 The following table presents revenue by geographical locations where the Company's services are delivered.
Shown below are the countries that account for the Company's revenue for the periods presented:

Fiscal Years Ended November 30,

2024 2023 2022
Revenue by geography:
Philippines
United States
India
Great Britain
Germany
Canada
Others
Total

Deferred revenue contract liabilities and deferred costs to obtain or fulfill a contract are not material.
NOTE 11—PENSION AND EMPLOYEE BENEFITS PLANS:
The Company has a 401(k) plan in the United States under which eligible employees may contribute up to
the maximum amount as provided by law. Employees become eligible to participate in the 401(k) plan on the
first day of the month after their employment date. The Company may make discretionary contributions under
the plan.
Employees in most of the Company's non-U.S. legal entities are covered by government mandated defined
contribution plans. During fiscal years 2024, 2023 and 2022, the Company contributed $105,087, $89,767
and
$83,792, respectively, to defined contribution plans.

Defined Benefit Plans

For eligible employees in the United States, the Company maintains a frozen defined benefit pension plan
(―the cash balance plan‖), which includes both a qualified and non-qualified portion. The pension benefit formula
for the cash balance plan is determined by a combination of compensation, age-based credits and annual
guaranteed interest credits. The qualified portion of the cash balance plan has been funded through contributions
made to a trust fund.
The Company maintains funded or unfunded defined benefit pension or retirement plans for certain eligible
employees in the Philippines, Malaysia, India, and France. Benefits under these plans are primarily based on
years of service and compensation during the years immediately preceding retirement or termination of
participation in the plans.
The Company's measurement date for all defined benefit plans and other post-retirement benefits is November
30. The plan assumptions for both the U.S. and non-U.S. defined benefit pension plans are evaluated annually
and are updated as deemed necessary. Net benefit costs related to defined benefit plans were $16,097,
$11,328 and
$9,437, during fiscal years 2024, 2023 and 2022, respectively.
Components of pension cost for the Company's defined benefit plans are as follows:

Fiscal Years Ended November 30,

2024 2023 2022
Service costs
Interest costs on projected benefit obligation
Expected return on plan assets
Amortization and deferrals, net
Settlement charges
Total pension costs
 Service costs are recorded in cost of services and selling, general and administrative expenses while the
remaining components of total pension costs are recorded within other expense (income), net in the
consolidated statements of operations.
The status of the Company's defined benefit plans is summarized below:

Fiscal Years Ended November 30,

2024 2023
Change in Benefit Obligation:
Benefit obligation at beginning of year $ 208,565 $ 209,166
Service costs 9,033 6,937
Interest costs 10,893 10,306
Actuarial losses (gains) 6,017 (1,942)
Benefits paid (17,161) (13,761)
Acquisitions — 12,499
Settlements (490) (14,771)
Foreign currency adjustments (2,992) 131
Projected obligation at end of year $ 213,865 $ 208,565

Change in Plan Assets:

Fair value of plan assets at beginning of year $ 126,752 $ 137,351
Actual return on assets 17,251 2,358
Settlements (83) (14,771)
Employer contributions 4,442 12,143
Benefits paid (12,279) (10,119)
Foreign currency adjustments (160) (210)
Fair value of plan assets at end of year $ 135,923 $ 126,752

Funded Status of Plans:

Unfunded status $ 77,942 $ 81,813

Amounts recognized in the consolidated balance sheet and recorded within other accrued liabilities and
other long-term liabilities as of November 30, 2024 and 2023 consist of the following:

As of November 30,
2024 2023
Current liability $ 16,694 $ 16,946
Non-current liability 61,248 64,867
Total $ 77,942 $ 81,813

The accumulated benefit obligation for all defined benefit pension plans was $213,461 and $188,058 at
November 30, 2024 and 2023, respectively.
 The following weighted-average rates were used in determining the benefit obligations as of November
30, 2024 and 2023:

As of November 30,
2024 2023
Discount rate
Interest crediting rate for cash balance plan
Expected rate of future compensation growth

The following weighted-average rates were used in determining the pension costs for the fiscal years ended
November 30, 2024 and 2023:

Fiscal Years Ended November 30,

2024 2023
Discount rate
Interest crediting rate for cash balance plan
Expected return on plan assets
Expected rate of future compensation growth

For the cash balance plan, the discount rate reflects the rate at which benefits could effectively be settled
and is based on current investment yields of high-quality corporate bonds. The Company uses an actuarially-
developed yield curve approach to match the timing of cash flows of expected future benefit payments by
applying specific spot rates along the yield curve to determine the assumed discount rate.
The range of discount rates utilized in determining the pension cost and projected benefit obligation of the
Company's defined benefit plans reflects a lower prevalent rate applicable to the frozen cash balance plan
for eligible employees in U.S. and a higher applicable rate for the unfunded defined benefit plan for certain
eligible employees in the Philippines, France and Malaysia. The plans outside the U.S. represented
approximately 40% and 39% of the Company's total projected benefit obligation for all defined benefit plans as
of November 30, 2024 and 2023, respectively.
Plan Assets
As of November 30, 2024 and 2023, plan assets for the cash balance plan consisted of common/collective
trusts (of which approximately 50% are invested in equity backed funds and approximately 50% are invested in
funds in fixed income instruments) and a private equity fund. The Company's targeted allocation was 50% equity
and 50% fixed income. The investment objectives for the plan assets are to generate returns that will enable
the plan to meet its future obligations. The Company's expected long-term rate of return was determined
based on the asset mix of the plan, projected returns, past performance and other factors. The following table
sets forth by level within the fair value hierarchy, total plan assets at fair value as of November 30, 2024 and
2023, including the cash balance plan and other funded benefit plans:

As of Quoted As of
Prices in Significa As of
As of Active nt Other Significa
Markets for nt

Cash and cash equivalents

Common/collective trusts:
Fixed income
U.S. large cap
U.S. small cap
International equity
Governmental bonds
Corporate bonds
Investment funds
Limited partnership — — —
Total investments

As of Quoted As of
Prices in Significa As of
As of Active nt Other Significa
Markets for nt

Cash and cash equivalents

Common/collective trusts:
Fixed income
U.S. large cap
U.S. small cap
International equity
Governmental bonds
Corporate bonds
Investment funds
Limited partnership
Total investments
 The Company's cash balance plan holds level 2 investments in common/collective trust funds that are public
investment vehicles valued using a net asset value (―NAV‖) provided by the manager of each fund. The NAV
is based on the underlying net assets owned by the fund, divided by the number of shares outstanding. The
NAV's unit price is quoted on a private market that may not be active. However, the NAV is based on the fair
value of the underlying securities within the fund, which are traded on an active market, and valued at the
closing price reported on the active market on which those individual securities are traded. The significant
investment strategies of the funds are as described in the financial statements provided by each fund. There are
no restrictions on redemptions from these funds. Level 3 investments are equity based funds that primarily invest
in domestic early stage capital funds.

Benefit Payments
The following table details expected benefit payments for the cash balance plan and other defined benefit plans:

Fiscal Years Ending November 30,

2025
2026
2027
2028
2029
Thereafter
Total

The Company expects to make approximately $2,375 in contributions during fiscal year 2025.
NOTE 12—LEASES:
The Company leases certain of its facilities and equipment under operating lease agreements, which expire in
various periods through 2037. The Company's finance leases are not material.
The following table presents the various components of operating lease costs:

Fiscal Years Ended November 30,

2024 2023 2022
Operating lease cost
Short-term lease cost
Variable lease cost
Sublease income
Total operating lease cost
 The following table presents a maturity analysis of expected undiscounted cash flows for operating leases on
an annual basis for the next five fiscal years and thereafter as of November 30, 2024:

Fiscal Years Ending November 30,

2025
2026
2027
2028
2029
Thereafter
Total payments
Less: imputed interest*
Total present value of lease payments
*Imputed interest represents the difference between undiscounted cash flows and discounted cash flows.

The following amounts were recorded in the consolidated balance sheet as of November 30, 2024 and
2023 related to the Company's operating leases:

As of November 30,
Operating leases Balance sheet location 2024 2023
Operating lease ROU assets Other assets, net
Current operating lease liabilities Other accrued liabilities
Non-current operating lease liabilities Other long-term liabilities

The following table presents supplemental cash flow information related to the Company's operating leases.
Cash payments related to variable lease costs and short-term leases are not included in the measurement of
operating lease liabilities, and, as such, are excluded from the amounts below:

Fiscal Years Ended November 30,

Cash flow information 2024 2023 2022
Cash paid for amounts included in the measurement of lease
liabilities
Non-cash ROU assets obtained in exchange for lease liabilities

The weighted-average remaining lease term and discount rate as of November 30, 2024 and 2023,
respectively, were as follows:

As of November 30,

Weighted-average remaining lease term (years) 4.50 4.88

Weighted-average discount rate
NOTE 13—INCOME TAXES:
The sources of income before the provision for income taxes are as follows:
Fiscal Years Ended November 30,
2024 2023 2022
United States
Foreign
Total income before income taxes

Provision for income taxes consists of the following:

Fiscal Years Ended November 30,

2024 2023 2022
Current tax provision:
Federal
State
Foreign

Deferred tax provision (benefit):

Federal
State
Foreign

Total income tax provision

The following presents the breakdown of net deferred tax liabilities after netting by taxing jurisdiction:

As of November 30,
2024 2023
Deferred tax assets
Deferred tax liabilities
Total net deferred tax liabilities

Net deferred tax liabilities consist of the following:

 As of November 30,
2024 2023
Assets:
Net operating losses
Accruals and other reserves
Depreciation and amortization
U.S. interest limitation carry forward
Share-based compensation expense
Deferred revenue
Tax credits
Foreign tax credit
Operating lease liabilities
Intercompany loans payable
Other
Gross deferred tax assets
Valuation allowance
Total deferred tax assets
Liabilities:
Intangible assets
Unremitted non-US earnings
Operating lease right-of-use assets
Total deferred tax liabilities
Net deferred tax liabilities

The valuation allowance relates primarily to certain state and foreign net operating loss carry forwards,
foreign deferred items and state credits. The Company's assessment is that it is not more likely than not that
these deferred tax assets will be realized.
A reconciliation of the statutory U.S. federal income tax rate to the Company's effective income tax rate is as
follows:
Fiscal Years Ended November 30,
2024 2023 2022
Federal statutory income tax rate
State taxes, net of federal income tax benefit
International rate difference
Withholding taxes
Uncertain tax benefits
Changes in valuation allowance
Impact of inclusion of foreign income (1)
Capital loss
Other (2)
Effective income tax rate

(1) Represents Subpart F income, Base Erosion and Anti-Abuse Tax (BEAT), and Global Intangible Low-Taxed Income (GILTI)
(less Section 250 deduction), net of associated foreign tax credits.

(2) Includes categories of reconciling items that are not individually equal to or greater than 5% for the fiscal year ended
November 30, 2024. Includes tax costs related to future legal entity restructuring for the fiscal year ended November 30,
2023.
 The Company's U.S. business has sufficient cash flow and liquidity to fund its operating requirements and
the Company expects and intends that profits earned outside the United States will be fully utilized and
reinvested outside of the United States with the exception of earnings of certain acquired non-U.S. entities.
The Company has recorded deferred tax liabilities related to non-U.S. withholding taxes on the earnings of its
non-U.S. subsidiaries likely to be repatriated in the future.
As of November 30, 2024, the Company had approximately $2,757,788 of undistributed earnings of its non-
U.S. subsidiaries for which it has not provided for non-U.S. withholding taxes and state taxes because such
earnings are intended to be reinvested indefinitely in international operations. It is not practicable to determine
the amount of applicable taxes that would be due if such earnings were distributed. Accordingly, the Company
has not provisioned
U.S. state taxes and non-U.S. withholding taxes on the non-U.S. legal entities for which the earnings
are permanently reinvested.
As of November 30, 2024, the Company had net operating loss carry forwards of approximately $312,542 and
$29,544 for federal and state purposes, respectively. The federal net operating loss carry forward and the state
net operating loss carry forwards will begin to expire in the fiscal year ending November 30, 2025. The Company
also had approximately $173,322 of foreign net operating loss carry forwards that will also begin to expire in
fiscal year ending November 30, 2025 if not used. In addition, the Company has approximately $10,670 of
various federal and state income tax credit carry forwards that, if not used, will begin to expire in the fiscal year
ending November 30, 2025. Utilization of the acquired loss carry forwards may be limited pursuant to Section
382 of the Internal Revenue Code of 1986.
The Company enjoys tax holidays in certain jurisdictions, primarily Algeria, China, Colombia, Costa Rica,
Dominican Republic, El Salvador, Estonia, Guatemala, Honduras, India, Jamaica, Jordan, Latvia,
Madagascar, Nicaragua, the Philippines and Türkiye. The tax holidays provide for lower or zero rates of
taxation and require various thresholds of investment and business activities in those jurisdictions. The
estimated tax benefits from the above tax holidays for fiscal years 2024, 2023, and 2022 were approximately
$17,332, $7,961, and $10,315, respectively.
The aggregate changes in the balances of gross unrecognized tax benefits, excluding accrued interest
and penalties, during fiscal years 2024, 2023, and 2022 were as follows:

Balance as of November 30, 2021

Additions based on tax positions related to the current year
Settlements
Lapse of statute of limitations
Balance as of November 30, 2022
Additions based on tax positions related to the current year
Additions based on tax positions related to the prior year / acquisition
Lapse of statute of limitations
Changes due to translation of foreign currencies
Balance as of November 30, 2023
Additions based on tax positions related to the current year
Additions based on tax positions related to the prior year / acquisition
Lapse of statute of limitations
Changes due to translation of foreign currencies
Settlements
Balance as of November 30, 2024

The Company conducts business globally and files income tax returns in various U.S. and non-U.S.
jurisdictions. The Company is subject to continuous examination and audits by various tax authorities.
Significant audits are underway in the United States and India. The Company is not aware of any material
exposures arising from these tax audits or in other jurisdictions not already provided for.
 Although timing of the resolution of audits and/or appeals is highly uncertain, the Company believes it is
reasonably possible that the total amount of unrecognized tax benefits as of November 30, 2024 could decrease
between $40,219 and $42,796 in the next twelve months. The Company is no longer subject to U.S. federal
income tax audit for returns covering years through fiscal year 2018. The Company is no longer subject to non-
U.S. or U.S. state income tax audits for returns covering years through fiscal year 2012 and fiscal year 2014,
respectively.
The liability for unrecognized tax benefits was $112,961 and $87,939 at November 30, 2024 and November
30, 2023, respectively, and is included in other long-term liabilities in the consolidated balance sheets. As of
November 30, 2024 and 2023, $60,512 and $52,779 of the total unrecognized tax benefits, net of federal benefit,
would affect the effective tax rate, if realized. The Company's policy is to include interest and penalties related to
income taxes, including unrecognized tax benefits, within the provision for income taxes. As of November 30,
2024 and 2023, the Company had accrued $12,613 and $8,617, respectively, in income taxes payable related to
accrued interest and penalties.
NOTE 14—COMMITMENTS AND CONTINGENCIES:
From time to time, the Company receives notices from third parties, including customers and suppliers,
seeking indemnification, payment of money, or other actions in connection with claims made against them.
Also, from time to time, the Company has been involved in various bankruptcy preference actions where the
Company was a supplier to the companies now in bankruptcy. In addition, the Company is subject to various
other claims, both asserted and unasserted, that arise in the ordinary course of business. The Company
evaluates these claims and records the related liabilities. It is possible that the liabilities ultimately incurred by
the Company could differ from the amounts recorded.
The Company does not believe that the above commitments and contingencies will have a material
adverse effect on the Company's results of operations, financial position or cash flows.
 NOTE 15—EARNINGS PER SHARE:
Basic and diluted earnings per common share (―EPS‖) are computed using the two-class method, which is an
earnings allocation formula that determines EPS for each class of common stock and participating security.
Fiscal Years Ended November 30,
2024 2023 2022
Basic earnings per common share:
Net income
Less: net income allocated to participating securities(1)
Net income attributable to common stockholders

Weighted average common shares - basic

Basic earnings per common share

Diluted earnings per common share:

Net income
Less: net income allocated to participating securities(1)
Net income attributable to common stockholders

Weighted-average number of common shares - basic

Effect of dilutive securities:
Stock options and restricted stock units
Weighted-average number of common shares - diluted

Diluted earnings per common share

(1) Restricted stock awards granted to employees by the Company are considered participating securities. Effective in the
fourth quarter of fiscal year 2023, restricted stock units granted are also considered participating securities.

NOTE 16—STOCKHOLDERS’ EQUITY:

Share repurchase program
In September 2021, the Company's board of directors authorized the repurchase of up to $500,000 of the
outstanding shares of Concentrix common stock from time to time as market and business conditions warrant,
including through open market purchases or Rule 10b5-1 trading plans. The repurchase program has no
termination date and may be suspended or discontinued at any time. During the fiscal years ended November
30, 2024 and 2023 under the share repurchase program, the Company repurchased 2,201 and 709 shares,
respectively, of Concentrix common stock for an aggregate purchase price of $136,096 and $63,958,
respectively. The share repurchases were made on the open market and the shares repurchased by the
Company are held in treasury for general corporate purposes. At November 30, 2024, approximately $154,030
remained available for share repurchases under the existing authorization from the Company's board of
directors.
During December 2024, the Company repurchased 151 shares of Concentrix common stock under the
repurchase program for an aggregate purchase price of $6,548.
In January 2025, the Company's board of directors extended the share repurchase program by authorizing an
increase of the amount remaining for share repurchases under the existing share repurchase authorization to
$600,000.
Dividends
During fiscal years 2024 and 2023, the Company paid the following dividends per share approved by the
Company's board of directors:

Announcement Date Record Date Per Share Dividend Amount Payment Date
January 19, 2023 January 30, 2023
March 29, 2023 April 28, 2023
June 28, 2023 July 28, 2023
September 27, 2023 October 27, 2023
January 24, 2024 February 5, 2024
March 26, 2024 April 26, 2024
June 26, 2024 July 26, 2024
September 25, 2024 October 25, 2024

On January 15, 2025, the Company announced a cash dividend of $0.33275 per share to stockholders of
record as of January 31, 2025, payable on February 11, 2025.
 ITEM 9. CHANGES AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND
FINANCIAL DISCLOSURES
None.
ITEM 9A. CONTROL AND PROCEDURES
Evaluation of disclosure controls and procedures
Based on the evaluation of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-
15(e) under the Exchange Act) as required by Rules 13a-15(b) or 15d-15(b) under the Exchange Act, our
principal executive officer and principal financial officer have concluded that as of the end of the period
covered by this report, our disclosure controls and procedures were effective to ensure that information required
to be disclosed by Concentrix in reports that it files or submits under the Exchange Act is recorded,
processed, summarized and reported within the time periods specified in SEC rules and forms, and include
controls and procedures designed to ensure that information required to be disclosed by us in such reports is
accumulated and communicated to our management, including the principal executive officer and principal
financial officer, as appropriate, to allow timely decisions regarding required disclosure.

Report of management on internal control over financial reporting

Management's Report on Internal Control over Financial Reporting, as of November 30, 2024, appears in
Part II, Item 8, of this Annual Report on Form 10-K, and is incorporated herein by reference.
The effectiveness of the Company's internal control over financial reporting, as of November 30, 2024,
has been audited by KPMG LLP, an independent registered public accounting firm, as stated in their report,
which appears in Part II, Item 8, of this Annual Report on Form 10-K.

Changes in internal control over financial reporting

There were no changes in our internal control over financial reporting that occurred during our fourth
fiscal quarter of fiscal year 2024 that have materially affected, or are reasonably likely to materially affect, our
internal control over financial reporting.

Limitations on controls
Our disclosure controls and procedures and internal control over financial reporting are designed to provide
reasonable assurance of achieving their objectives as specified above. Management does not expect,
however, that our disclosure controls and procedures or our internal control over financial reporting will prevent
or detect all error and fraud. Any control system, no matter how well designed and operated, is based upon
certain assumptions and can provide only reasonable, not absolute, assurance that its objectives will be met.
Further, no evaluation of controls can provide absolute assurance that misstatements due to error or fraud will
not occur or that all control issues and instances of fraud, if any, within the Company have been detected.
ITEM 9B. OTHER INFORMATION
Rule 10b5-1 trading arrangements
During the three months ended November 30, 2024, none of our directors or officers adopted or terminated
a ―Rule 10b5-1 trading arrangement‖ or ―non-Rule 10b5-1 trading arrangement,‖ as those terms are defined in
Item 408 of Regulation S-K.
ITEM 9C. DISCLOSURE REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONS
Not applicable.
 PART III
ITEM 10. DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE
Certain information required by this Item 10 is incorporated by reference to the material under the headings
―Board of Directors,‖ ―Board Committees,‖ ―Proposals Requiring Your Vote—Proposal No. 1: Election of
Directors,‖ and ―Our Executive Officers‖ in the Company's definitive Proxy Statement for the 2025 Annual
Meeting of Stockholders, which we will file with the SEC not later than April 1, 2025.
Item 405 of Regulation S-K calls for disclosure of any known late filing or failure by an insider to file a report
required by Section 16(a) of the Exchange Act. To the extent disclosure for delinquent reports is being made, it
can be found under the caption ―Delinquent Section 16(a) Reports‖ in the Company's definitive Proxy Statement
for the 2025 Annual Meeting of Stockholders, which we will file with the SEC not later than April 1, 2025, and is
incorporated herein by reference.
Our Code of Ethical Business Conduct, with which our directors, officers and staff must comply,
establishes legal and ethical standards for conducting our business, including in accordance with applicable
Nasdaq listing standards and SEC regulations. Our Code of Ethical Business Conduct is available free of
charge on the ―Governance—Governance Documents‖ page of the Investor section of our website at
[Link], and a copy may also be obtained, upon request, from our Corporate Secretary at 39899
Balentine Drive, Suite 235, Newark, California, 94560. Future waivers from, or amendments to, our Code of
Ethical Business Conduct that apply to our principal executive officer, principal financial officer, principal
accounting officer or controller or persons performing similar functions will be timely posted on the webpage
referenced in this paragraph.
We have an insider trading policy governing the purchase, sale, and other dispositions of our securities that
applies to all of our personnel, including directors, officers, game-changers, and other covered persons. We also
follow such procedures, as applicable, for the repurchase of our securities. We believe that our insider trading
policy and repurchase procedures are reasonably designed to promote compliance with insider trading laws,
rules, and regulations, and listing standards applicable to us. A copy of our insider trading policy, the Concentrix
Corporation Securities Trading Policy, is filed as Exhibit 19.1 to this Form 10-K.
ITEM 11. EXECUTIVE COMPENSATION
The information required by this Item 11 is incorporated by reference to the material under the headings
―Board Committees—Compensation Committee,‖ ―Director Compensation,‖ ―Compensation Discussion and
Analysis,‖ ―2024 Summary Compensation Table,‖ ―Grants of Plan-Based Awards in Fiscal Year 2024,‖
―Outstanding Equity Awards at 2024 Fiscal Year-End,‖ ―Option Exercises and Stock Vested in Fiscal Year 2024,‖
―Pension Benefits,‖ ―Potential Payments upon Termination or in Connection with a Change of Control,‖ ―CEO Pay
Ratio,‖ ―Pay Versus Performance,‖ and ―Corporate Governance—Risk Management‖ in the Company's
definitive Proxy Statement for the 2025 Annual Meeting of Stockholders, which we will file with the SEC not later
than April 1, 2025.
ITEM 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND
RELATED STOCKHOLDER MATTERS
The information required by this Item 12 is incorporated by reference to the material under the headings
―Beneficial Ownership of Securities‖ and ―Equity Compensation Plan Information‖ in the Company's definitive
Proxy Statement for the 2025 Annual Meeting of Stockholders, which we will file with the SEC not later than
April 1, 2025.
ITEM 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS AND DIRECTOR
INDEPENDENCE
The information required by this Item 13 is incorporated by reference to the material under the headings
―Corporate Governance—Related Party Transactions‖ and ―Board of Directors—Director Independence‖ in the
Company's definitive Proxy Statement for the 2025 Annual Meeting of Stockholders, which we will file with the
SEC not later than April 1, 2025.
 ITEM 14. PRINCIPAL ACCOUNTING FEES AND SERVICES
The information required by this Item 14 is incorporated by reference to the material under the heading
―Proposals Requiring Your Vote—Proposal No. 2: Ratification of Appointment of Independent Registered
Public Accounting Firm‖ in the Company's definitive Proxy Statement for the 2025 Annual Meeting of
Stockholders, which we will file with the SEC not later than April 1, 2025.

PART IV
ITEM 15. EXHIBITS AND FINANCIAL STATEMENT SCHEDULES
(a)(1) Financial Statements
The consolidated financial statements of the Company filed as part of this Annual Report on Form 10-K are
included in Item 8. Financial Statements and Supplementary Data.

(a)(2) Financial Statement Schedules

Schedules Omitted
Schedules other than Schedule II are omitted because they are not required or applicable under instructions
contained in Regulation S-X or because the information called for is shown in the consolidated financial
statements.
CONCENTRIX
SCHEDULE II—VALUATION AND QUALIFYING ACCOUNTS
For the Fiscal Years Ended November 30, 2024, 2023 and
2022 (in thousands)

Additions/
Deductions
Charged to
Balances Revenue Additions Reclassifications Balances
at and from and at End of
Beginning Expense, Acquisitio Write-offs Fiscal
of Fiscal net ns Year
Year
Fiscal Year Ended November 30,
2024
Allowance for deferred tax assets
Fiscal Year Ended November 30, 2023
Allowance for deferred tax assets
Fiscal Year Ended November 30, 2022

2.1 Agreement and Plan of Merger, dated as of November 19, 2021, by and among
Concentrix Corporation, CNXC Merger Sub, Inc., ProKarma Holdings Inc. and Carlyle
Partners VI Holdings, L.P. (incorporated by reference to Exhibit 2.1 to the Company's
Current Report on Form 8-K filed on November 24, 2021).*
2.2 First Amendment to Agreement and Plan of Merger, dated as of December 20, 2021, by
and among Concentrix Corporation, CNXC Merger Sub, Inc., ProKarma Holdings Inc.
and Carlyle Partners VI Holdings, L.P. (incorporated by reference to Exhibit 2.1 to the
Company's Current Report on Form 8-K filed on December 23, 2021).*
2.3 Share Purchase and Contribution Agreement, dated June 12, 2023, by and among
Concentrix Corporation, OSYRIS S.à r.l., Marnix Lux SA, the other beneficiaries party
thereto, and Sandrine Asseraf as the PoA Seller Representative (incorporated by
reference to Exhibit 10.1 to the Company's Current Report on Form 8-K filed on June 12,
2023).*
2.4 First Amendment to Share Purchase and Contribution Agreement, dated July 14, 2023,
by and among Concentrix Corporation, OSYRIS S.à r.l., Marnix Lux SA, Sandrine
Asseraf as the PoA Seller Representative, Priscilla Maters, as the representative of the
GBL Sellers and Frédéric Jousset, and Sapiens, as the representative of the Non-PoA
Sellers (incorporated by reference to Exhibit 10.1 to the Company's Current Report on
Form 8-K filed on July 17, 2023).*
3.1 Composite Amended and Restated Certificate of Incorporation of Concentrix
Corporation filed on December 2, 2020, as amended by the Certificate of Amendment of
the Certificate of Incorporation of Concentrix Corporation, filed October 28, 2024.
3.2 Amended and Restated Bylaws of Concentrix Corporation, as amended.

3.3 Amended and Restated Bylaws of Concentrix Corporation, as amended (redlined).

4.1 Description of Securities.

4.2 Indenture, dated as of August 2, 2023, by and between Concentrix Corporation and U.S.
Bank Trust Company, National Association, as trustee (incorporated by reference to
Exhibit 4.1 to the Company's Current Report on Form 8-K filed on August 2, 2023).

4.3 First Supplemental Indenture, dated as of August 2, 2023, by and between Concentrix
Corporation and U.S. Bank Trust Company, National Association, as trustee (incorporated
by reference to Exhibit 4.2 to the Company's Current Report on Form 8-K filed on August
2, 2023).

4.4 Second Supplemental Indenture, dated as of August 2, 2023, by and between Concentrix
Corporation and U.S. Bank Trust Company, National Association, as trustee (incorporated
by reference to Exhibit 4.3 to the Company's Current Report on Form 8-K filed on August
2, 2023).

4.5 Third Supplemental Indenture, dated as of August 2, 2023, by and between Concentrix
Corporation and U.S. Bank Trust Company, National Association, as trustee (incorporated
by reference to Exhibit 4.4 to the Company's Current Report on Form 8-K filed on August
2, 2023).

10.1 Amendment and Restatement Agreement, dated as of April 21, 2023, by and among
Concentrix Corporation, the lenders party thereto, JPMorgan Chase Bank, N.A., and
Bank of America, N.A. (incorporated by reference to Exhibit 10.1 to the Company's
Current Report on Form 8-K filed on April 26, 2023).
10.2 Receivables Financing Agreement, dated as of October 30, 2020, by and among
Concentrix Receivables, Inc., as borrower, the Company, as initial servicer, the lenders
party thereto, and PNC Bank, National Association, as administrative agent
(incorporated by reference to Exhibit
10.7 to Amendment No. 2 to the Company's Registration Statement on Form 10 filed on
October 30, 2020).
10.3 Receivables Purchase Agreement, dated as of October 30, 2020, by and among
Concentrix Receivables, Inc., the Company, as servicer, and the subsidiaries of the
Company named therein, as originators (incorporated by reference to Exhibit 10.8 to
Amendment No. 2 to the Company's Registration Statement on Form 10 filed on October
30, 2020).
10.4 First Omnibus Amendment, dated as of May 5, 2021, by and among the Company, as
servicer, Concentrix Receivables, Inc., as borrower, the subsidiaries of the Company
named therein, as originators, the lenders party thereto, and PNC Bank, National
Association, as administrative agent (incorporated by reference to Exhibit 10.1 to the
Company's Quarterly Report on Form 10- Q filed on July 9, 2021).
10.5 Second Amendment to Receivables Financing Agreement, dated as of July 6, 2022,
by and among Concentrix Receivables, Inc., as borrower, the Company, as servicer, the
lenders party thereto, and PNC Bank, National Association, as administrative agent
(incorporated by reference to Exhibit 10.2 to the Company's Quarterly Report on Form
10-Q filed on July 8, 2022).
10.6 Third Amendment to Receivables Financing Agreement, dated as of April 25, 2024, by
and among Concentrix Receivables, Inc., as borrower, the Company, as servicer, the
group agents and the lenders party thereto, and PNC Bank, National Association, as
administrative agent (incorporated by reference to Exhibit 10.1 to the Company's
Current Report on Form 8-K filed on April 26, 2024).
10.7 Fourth Amendment to Receivables Financing Agreement, dated as of January 14, 2025,
by and among Concentrix Receivables, Inc., as borrower, the Company, as servicer, the
group agents and the lenders party thereto, and PNC Bank, National Association, as
administrative agent (incorporated by reference to Exhibit 10.1 to the Company's
Current Report on Form 8-K filed on January 21, 2025).
10.8 Put Option Agreement, dated as of March 29, 2023, by and among Concentrix
Corporation, OSYRIS S.à r.l., Marnix Lux SA, the other beneficiaries party thereto, and
Sandrine Asseraf as the PoA Seller Representative, including the form of Sellers' Note
set forth as Schedule 7 thereto (incorporated by reference to Exhibit 10.1 to the
Company's Current Report on Form 8-K filed on March 31, 2023).*
10.9 Investor Rights Agreement, dated as of March 29, 2023, by and among Concentrix
Corporation and the initial stockholders party thereto (incorporated by reference to
Exhibit 10.2 to the Company's Current Report on Form 8-K filed on March 31, 2023).*

10.10 Commitment Letter, dated as of March 29, 2023, by and between Concentrix Corporation
and JPMorgan Chase Bank, N.A (incorporated by reference to Exhibit 10.3 to the
Company's Current Report on Form 8-K filed on March 31, 2023).
10.11 Sellers' Note, dated September 25, 2023, by and among Concentrix Corporation and
certain holders party thereto (incorporated by reference to Exhibit 10.3 to the Company's
Current Report on Form 8-K filed on September 25, 2023).
10.12 Form of Stock Restriction Agreement by and between Concentrix Corporation and the
shareholders of Marnix Lux SA party thereto (incorporated by reference to Exhibit E to
Exhibit 10.1 to the Company's Current Report on Form 8-K filed on July 17, 2023).
10.13 Offer Letter, dated as of November 24, 2020, by and between the Company and
Christopher Caldwell (incorporated by reference to Exhibit 10.1 to the Company's Current
Report on Form 8- K filed on November 25, 2020).†
10.14 Concentrix Corporation Amended and Restated 2020 Stock Incentive Plan
(incorporated by reference to Exhibit 10.1 to the Company's Current Report on Form
8-K filed on October 29, 2024).†
10.15 Form of Restricted Stock Award Agreement under the Concentrix Corporation 2020
Stock Incentive Plan (incorporated by reference to Exhibit 10.1 to the Company's
Current Report on Form 8-K filed on January 22, 2021).†
10.16 Form of Restricted Stock Unit Award Agreement under the Concentrix Corporation 2020
Stock Incentive Plan (Non-Employee Directors).†

10.17 Form of Restricted Stock Unit Award Agreement under the Concentrix Corporation 2020
Stock Incentive Plan (incorporated by reference to Exhibit 10.11 to the Company's
Annual Report on Form 10-K filed on February 16, 2021).†
10.18 Form of Stock Option Award Agreement under the Concentrix Corporation 2020 Stock
Incentive Plan (incorporated by reference to Exhibit 10.2 to the Company's Current Report
on Form 8-K filed on January 22, 2021).†
10.19 Form of Restricted Stock Award Agreement under the Concentrix Corporation 2020
Stock Incentive Plan (2022) (incorporated by reference to Exhibit 10.15 to the
Company's Annual Report on Form 10-K filed on January 28, 2022).†
10.20 Form of Restricted Stock Unit Award Agreement under the Concentrix Corporation 2020
Stock Incentive Plan (2022) (incorporated by reference to Exhibit 10.16 to the
Company's Annual Report on Form 10-K filed on January 28, 2022).†
10.21 Form of Performance Restricted Stock Unit Award Agreement under the Concentrix
Corporation 2020 Stock Incentive Plan (incorporated by reference to Exhibit 10.17 to the
Company's Annual Report on Form 10-K filed on January 28, 2022).†
10.22 Form of Restricted Stock Unit Award Agreement under the Concentrix Corporation 2020
Stock Incentive Plan (2023) (incorporated by reference to Exhibit 10.20 to the
Company's Annual Report on Form 10-K filed on January 29, 2024).†

10.23 Concentrix Corporation 2020 Employee Stock Purchase Plan, as amended.†

10.24 Concentrix Corporation Change of Control Severance Plan (incorporated by reference to

Exhibit 10.9 to the Company's Current Report on Form 8-K filed on December 2, 2020).†
10.25 Form of Indemnification Agreement between the Company and individual directors and
officers (incorporated by reference to Exhibit 10.4 to Amendment No. 1 to the
Registration Statement on Form 10 filed by Concentrix Corporation on October 13, 2020
(File No. 001-39494)).†
10.26 Service Agreement, effective as of January 7, 2019, by and between Concentrix CVG
CMG UK Limited and Cormac Twomey (incorporated by reference to Exhibit 10.16 to the
Company's Annual Report on Form 10-K filed on February 16, 2021).†
16.1 Letter from KPMG LLP (incorporated by reference to Exhibit 16.1 to the Company's
Current Report on Form 8-K filed on October 30, 2024).
19.1 Concentrix Corporation Securities Trading Policy.

21.1 Subsidiaries of the Company.

23.1 Consent of KPMG LLP.
24.1 Power of Attorney (included on signature page of this report).
 31.1 Certification of Chief Executive Officer pursuant to Rule 13a- 14(a) and Rule 15d-14(a)
of the Securities Exchange Act of 1934, as amended.
31.2 Certification of Chief Financial Officer pursuant to Rule 13a- 14(a) and Rule 15d-14(a)
of the Securities Exchange Act of 1934, as amended.
32.1 Certification of Chief Executive Officer and Chief Financial Officer pursuant to 18 U.S.C.
1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
97.1 Concentrix Corporation Compensation Clawback Policy (incorporated by reference to
Exhibit 97.1 to the Company's Annual Report on Form 10-K filed on January 29, 2024).

[Link] Inline XBRL Instance Document - the instance document does not appear in the Interactive
Data File because its XBRL tags are embedded within the Inline XBRL document.

[Link] Inline XBRL Taxonomy Extension Schema Document.

[Link] Inline XBRL Taxonomy Extension Calculation Linkbase Document.

[Link] Inline XBRL Taxonomy Extension Label Linkbase Document.
[Link] Inline XBRL Taxonomy Extension Presentation Linkbase

Document. [Link] Inline XBRL Taxonomy Extension Definition

Linkbase Document.
104 Cover Page Interactive Data File (Embedded within the Inline XBRL document and included
in Exhibit 101).
* Schedules and exhibits have been omitted pursuant to Item 601(b)(2) of Regulation S-K. Concentrix
Corporation hereby undertakes to furnish copies of any of the omitted schedules and exhibits upon
request by the U.S. Securities and Exchange Commission.

† Management contract or compensatory plan or arrangement required to be filed as an exhibit pursuant to

Item 15(b) of Form 10-K.
ITEM 16. FORM 10-K SUMMARY
None.
 SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant
has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
Date: January 28, 2025

CONCENTRIX CORPORATION

By:
President and Chief Executive Officer

EQUITY COMPENSATION PLAN INFORMATION

The following table summarizes information with respect to our equity compensation plans as of November
30, 2024:

(c)
Number of Securities
Remaining Available
(a) for Future Issuance
Number of Securities (b) Under Equity
to be Issued Upon Weighted Average Compensation Plans
Exercise of Exercise Price of (Excluding Securities
Outstanding Options, Outstanding Options, Reflected in Column
Plan Category Warrants and Rights(1) Warrants and Rights (a))
Equity compensation plans approved by
stockholders(2)
Equity compensation plans not approved by
stockholders(3)

Total

(1) Reflects awards outstanding under the Concentrix Corporation Amended and Restated 2020 Stock Incentive Plan, as amended
(―2020 Stock Incentive Plan‖). Includes 3,227,428 unvested time-based restricted stock units (―RSUs‖), 776,534 unvested
performance-based RSUs (at target), and 228,832 stock options with a weighted average remaining term of 3.78 years. The
RSUs are not included in the calculation of the weighted average exercise price in column (b).
(2) Reflects shares available for issuance under (a) the 2020 Stock Incentive Plan and (b) the Concentrix Corporation 2020
Employee Stock Purchase Plan, as amended (the ―ESPP‖). Under the ESPP, qualifying employees may purchase shares of
Common Stock at a discount to the market value. As of November 30, 2024, 2,265,700 shares of Common Stock remained
available for grant under the 2020 Stock Incentive Plan and 892,709 shares of Common Stock remained available for issuance
under the ESPP.
(3) Reflects shares available for issuance upon the exercise of certain outstanding stock options originally granted under the
ProKarma Holdings Inc. (―PK‖) 2016 Long-Term Incentive Plan and assumed by the Company in connection with its acquisition
of PK in December 2021.
 BENEFICIAL OWNERSHIP OF SECURITIES

On the record date, January 28, 2025, our outstanding voting securities consisted of 64,337,846 shares
of Common Stock. The following tables set forth the number of shares of Common Stock that are beneficially
owned by each of our directors and named executive officers and each stockholder that we believe to be the
beneficial owner of more than 5% of the outstanding Common Stock, in each case as of the record date of
January 28, 2025.

As used in this information statement, ―beneficial ownership‖ means that a person has, or may have within 60
days of January 28, 2025, the sole or shared power to vote or direct the voting of a security or the sole or
shared investment power with respect to a security (that is, the power to dispose or direct the disposition of a
security), or both. Unless otherwise indicated in the footnotes below, each individual or entity identified below
has sole voting and investment power with respect to such securities and no
securities have been pledged.

Number of
Shares of Number of
Common Stock Shares of
Number of Subject to Common Stock
Shares of Options That May Be
Directors and Named Common Stock Exercisable Settled within 60 Total Beneficial Percentage
Executive Officers Owned within 60 Days Days Ownership Ownership
Chris Caldwell

Teh-Chien Chou

LaVerne H. Council

Jennifer Deason

Olivier Duha(1)

Craig Gibson(2)

Nicolas Gheysens

Jane Fogarty

Kathryn Hayley(3)

Kathryn Marinello

Dennis Polk

Ann Vezina

Andre Valentine

Cormac Twomey

Rick Rosso

All executive officers and

directors as a group (14
persons)

* Represents less than 1% of the Company's Common Stock.

(1) Includes 322,066 shares held by Celeste Investissements, a societe anonyme, organized under the Laws of Belg ium, and
36,041 shares held by Liberty Management, a societe a responsabilite limitee, organized under the laws of Belgium.

(2) Includes 969 shares of restricted stock held by Mr. Gibson that were issued in connection with the combination with Webhelp.
Such shares vest in full if the share price of our Common Stock reaches $170.00 per share within seven years from September
25, 2023 (based on daily volume weighted average prices measured over a specific period), or if within three years from
September 25, 2023 we have a change of control with per share consideration of at least $150.00. Such shares of restricted
stock are not entitled to dividends and Mr. Gibson has waived his rights as a holder of such shares to vote on any matter
submitted to the holders of our Common Stock.
(3) Includes 3,035 shares held by the KJH Investment Trust for which Ms. Hayley is the trustee and beneficiary.
 Number of Shares
Principal Stockholders and Address Beneficially Owned Percentage Ownership
Group Bruxelles Lambert (1)
24 avenue Marnix
1000 Brussels, Belgium

The Vanguard Group (2)

100 Vanguard Blvd
Malvern, PA 19355

MiTAC Holdings Corporation (3)

No. 202, Wenhua 2nd Road
Guishan District, Taoyuan City 333
Taiwan

Impactive Capital LP (4)

450 West 14 Street, 12th Floor
New York City, NY 10014

BlackRock, Inc. (5)

55 East 52nd Street
New York, NY 10022

Synnex Technology International Corporation (6)

4F, No. 75, Sec. 3, Minsheng E. Road
Zhongshan District, Taipei City 104
Taiwan

(1) Based solely on information contained in a Schedule 13D filed with the SEC on October 5, 2023 by GBL, this amount
represents 35,964 shares of Common Stock held by FINPAR V SA (―FINPAR V‖), 38,623 shares of Common Stock held by
FINPAR VI SA (―FINPAR VI‖), and 8,699,080 shares of Common Stock held by Sapiens S.àr.l. (―Sapiens‖). FINPAR V has
shared voting and dispositive power over 35,964 shares of Common Stock, FINPAR VI has shared voting and dispositive
power over 38,623 shares of Common Stock, and Sapiens has shared voting and dispositive power over 8,699,080 shares of
Common Stock. GBL Verwaltung S.A. (―GBLV‖) is the parent company of Sapiens, and therefore may be deemed to
beneficially own the 8,699,080 shares of Common Stock held by Sapiens. GBL is the parent of GBLV, FINPAR V, and FINPAR
VI and therefore may be deemed to beneficially own the 8,773,667 shares of Common Stock directly held by GBL, FINPAR V,
and FINPAR VI.
(2) Based solely on information contained in Amendment No. 3 to Schedule 13G filed with the SEC on February 13, 2024 by The
Vanguard Group, which reported that it did not have sole voting power over any shares of Common Stock and had sole
dispositive power over 5,286,294 shares of Common Stock, shared voting power over 30,239 shares of Common Stock, and
shared dispositive power over 77,599 shares of Common Stock.
(3) Based solely on information contained in Amendment No. 4 to Schedule 13G filed with the SEC on February 6, 2024, this
amount includes 302,102 shares of Common Stock held by Silver Star Developments Ltd. (―SSDL‖), 2,135,489 shares of
Common Stock held by MiTAC International Corporation (―MIC‖), and 1,977,944 shares of Common Stock held by MiTAC
Holdings Corporation (―MHC‖). SSDL is a wholly-owned subsidiary of MIC and MIC is a wholly-owned subsidiary of MHC. MHC
has sole voting and sole dispositive power over 4,415,535 shares of Common Stock.
(4) Based solely on information contained in Amendment No. 1 to Schedule 13D filed with the SEC on August 7, 2024, which
reported that that the shares of Common Stock are beneficially held by (i) Impactive Capital LLC, as the general partner of
Impactive Capital LP, the investment manager of the funds and/or accounts that directly own the shares of Common Stock, (ii)
Lauren Taylor Wolfe, as a Managing Member of Impactive Capital LLC, and (iii) Christian Asmar, as a Managing Member of
Impactive Capital LLC (collectively, the ―Impactive Holders‖). The Impactive Holders have shared voting and shared dispositive
power over 4,375,125 shares of Common Stock.
(5) Based solely on information contained in Amendment No. 3 to Schedule 13G filed with the SEC on January 29, 2024 by
BlackRock, Inc., which reported that it had sole voting power over 3,855,799 shares of Common Stock and sole dispositive
power over 3,982,052 shares of Common Stock.
(6) Based solely on information contained in Amendment No. 2 to Schedule 13G filed with the SEC on February 6, 2024, this
amount represents 3,545,840 shares of Common Stock held by Peer Developments Ltd. Peer Developments Ltd. is a wholly-
owned subsidiary of Synnex Technology International Corporation. Synnex Technology International Corporation has sole
voting and sole dispositive power over 3,545,840 shares of Common Stock.
 OUR EXECUTIVE OFFICERS

Information regarding each of our executive officers and their relevant business experience is
summarized below.
 2024 SUMMARY COMPENSATION TABLE

The following table sets forth the compensation awarded to, earned by or paid to our named executive
officers for the fiscal years ended November 30, 2024, 2023 and 2022.

Change
Non-Equity in
Stock Option Incentive Plan Pension All Other
Name and Salary Bonus Awards Awards Compensation Value Compensation Total
Principal Position Year ($) ($) ($)(1) ($)(1) ($)(2) ($)(3) ($)(4) ($)
2024
Chris Caldwell
2023
President and CEO
2022

2024
Andre Valentine
Chief Financial 2023
Officer
2022

Cormac Twomey (5) 2024

EVP, Global
2023
Operations and
Delivery 2022
2024
Craig Gibson(5)
EVP, Global Sales
and Account
Management

2024
Jane Fogarty
2023
EVP, Legal
2022

2024
Rick Rosso(6)
EVP, Practices and 2023
Catalyst
2022

(1) Represents the aggregate fair values of stock awards and option awards granted to our named executive officers, as
determined in accordance with ASC Topic 718, on the applicable grant date or, if earlier, the service inception date. The grant
date fair value of RSUs was determined by multiplying the number of shares by $89.28, the closing price of the Common Stock
on the grant date. The grant date fair value of PRSUs was determined by multiplying the target number of shares by a reduced
price per share of $85.71 because the unvested PRSUs do not receive dividends. For other valuation assumptions used to
calculate the fair value of our stock awards granted in fiscal year 2024, see Note 4 ―Share-Based Compensation‖ to the
consolidated financial statements included in our Annual Report on Form 10-K for the fiscal year ended November 30, 2024.
The grant date fair values of the NEOs' 2024 PRSU awards, assuming achievement of the maximum performance level, would
be: Mr. Caldwell, $10,367,996; Mr. Valentine, $1,497,525; Mr. Twomey, $1,574,321; Mr. Gibson, $873,556; Ms. Fogarty,
$806,360; and Mr. Rosso, $873,556.

(2) For fiscal year 2024, represents performance-based awards under the SMIP earned in fiscal year 2024 and paid in fiscal year
2025.
(3) Mr. Valentine's accumulated benefit under the Convergys frozen defined benefit pension plan increased by $30,738 in fiscal
year 2024. The pension plan, which includes a qualified and a non-qualified portion, was assumed by Concentrix in connection
with our acquisition of Convergys in 2018. The assumptions used to calculate the change in pension value are described in
Note 1 to the Pension Benefits table below.
(4) The amounts shown in the All Other Compensation column for fiscal year 2024 include the following:

Company Dividend
Contributions Payments on Supplemental Perquisites
to Defined Unvested Taxes on Life Long-Term and Other
Contribution Equity Life Insurance Insurance Disability Personal
Plans(a) Awards(b) Premiums(c) Premiums(d) Premiums(e) Benefits(f) Total
C. Caldwell
A. Valentine
C. Twomey
C. Gibson
J. Fogarty
R. Rosso

(a) Represents matching contributions made to the NEO's 401(k) Plan account or, in the case of Messrs. Twomey and
Gibson, Company contributions to the Company's defined contribution plan in the United Kingdom.

(b) Represents dividends paid on unvested Concentrix restricted stock awards, unvested Concentrix restricted stock units
and unvested TD SYNNEX restricted stock awards held by the NEO. The dividends on the unvested TD SYNNEX
restricted stock were paid by TD SYNNEX as the issuer of the equity, but the amounts are included in this column
because the benefit relates to the NEO's continuing employment (i.e., the restricted stock would be forfeited if the NEO's
employment with Concentrix terminates).
(c) Represents group term life insurance premiums paid on behalf of the NEO.

(d) Represents the payment of taxes incurred by the NEO in connection with the group term life insurance benefit.
(e) Represents supplemental long-term disability premiums paid on behalf of the NEO.

(f) Represents a car allowance of £10,000 that is a legacy benefit from Mr. Gibson's employment with Webhelp prior to our
combination with Webhelp in September 2023.

(5) Messrs. Twomey and Gibson's fiscal year 2024 base salary, SMIP award, and amounts included under ―All Other
Compensation‖ were paid in British pounds and converted to the U.S. dollar amounts included in the table by using the 2024
fiscal year-end exchange rate of 1 GBP to $1.2736.

(6) In January 2024, Mr. Rosso transitioned to a non-executive officer role with Concentrix.
 GRANTS OF PLAN-BASED AWARDS IN FISCAL YEAR 2024

The following table sets forth information regarding grants of plan-based awards to each of our named
executive officers for the fiscal year ended November 30, 2024.

All Other Grant

Estimated Future Payouts Under Stock Date Fair
Non-Equity Incentive Plan Estimated Future Payouts Under Awards; Value of
Awards(2) Equity Incentive Plan Awards(3) Number Stock and
of Shares Option
Grant Approval Threshold Target Maximum Threshold Target Maximum of Stock(4) Awards(5)
Name Date Date(1) ($) ($) ($) (#) (#) (#) (#) ($)
Chris Caldwell

Andre Valentine

Cormac
Twomey(6)

Craig Gibson(6)

Jane Fogarty

Rick Rosso

(1) Represents the date on which the Compensation Committee took action to approve the corresponding equity award. All grants
were made on the fourth trading day after the conclusion of the trading blackout period during which the awards were
approved, consistent with our equity award grant policy.

(2) The amounts shown in these columns reflect each named executive officer's threshold, target, and maximum award under the
SMIP, with the potential for each executive officer's actual award under the plan to exceed or be less than the target depending
upon company performance. The actual SMIP awards for fiscal year 2024 are reflected in the Non-Equity Incentive Plan
Compensation column of the 2024 Summary Compensation Table.
(3) The amounts shown in these columns reflect the threshold, target, and maximum number of shares of Common Stock that may
vest under each named executive officer's February 2024 PRSUs based on company performance over the three-year
performance period ending November 30, 2026, as described in more detail under ―Compensation Discussion and Analysis—
Performance-Based, Long-Term Equity Incentives.‖
(4) Represents the number of RSUs granted to each NEO in fiscal year 2024, all of which will vest in one-third tranches on each of
the first three anniversaries of the grant date.

(5) Represents the aggregate fair values of stock awards granted to our named executive officers, as determined in accordance
with ASC Topic 718, on the applicable grant date or, if earlier, the service inception date. The grant date fair value of RSUs was
determined by multiplying the number of shares by $89.28, the closing price of the Common Stock on the grant date. The grant
date fair value of PRSUs was determined by multiplying the target number of shares by a reduced price per share of $85.71
because the unvested PRSUs do not receive dividends. For other valuation assumptions used to calculate the fair value of our
stock and option awards, see Note 4 ―Share-Based Compensation‖ to the consolidated financial statements included in our
Annual Report on Form 10-K for the fiscal year ended November 30, 2024.
(6) Messrs. Twomey and Gibson's threshold, target, and maximum SMIP award amounts were converted from British pounds to
U.S. dollars by using the 2023 fiscal year-end exchange rate of 1 GBP to $1.2736.
 OUTSTANDING EQUITY AWARDS AT 2024 FISCAL YEAR-END

The following table sets forth information regarding outstanding equity awards for each of our named
executive officers as of November 30, 2024.

Option Awards(1) Stock Awards

Equity
Incentive
Equity Plan
Incentive Awards:
Plan Market or
Number of Number of Market Awards: Payout
Securities Securities Number of Value of Number of Value of
Underlying Underlying Shares of Shares of Unearned Unearned
Unexercised Unexercised Stock That Stock That Units That Units That
Options Options Option Option Have Not Have Not Have Not Have Not
Exercisable Unexercisable Exercise Expiration Vested(2) Vested(2)(3) Vested(4) Vested(3)
Name (#) (#) Price ($) Date (#) ($) (#) ($)
Chris
Caldwell

Andre
Valentine

Cormac
Twomey

Craig
Gibson

Jane
Fogarty

Rick
Rosso

(1) Prior to the spin-off, Mr. Caldwell was granted option awards by TD SYNNEX under its 2013 Stock Incentive Plan. In
connection with the spin-off, each of these option awards was converted into a TD SYNNEX option and a Concentrix option
with respect to the same number of shares as the original option, with an adjustment to the exercise prices to preserve the
same ratio of the exercise price to the per share value of the underlying stock as existed prior to the spin-off. This table includes
only the converted Concentrix option awards granted under the Concentrix 2020 Stock Incentive Plan, as well as any option
awards granted by Concentrix following the spin-off. All option awards listed in these columns vested and became exercisable
as to 20% of the shares on the first anniversary of the grant date and 1/60th of the shares monthly thereafter over the following
four-year period, except for the grant scheduled to expire on January 20, 2031, which vested as to 20% on the first anniversary
of October 7, 2020, the scheduled grant date for the fiscal year 2020 equity awards that were delayed due to the spin-off, and
1/60th of the shares monthly thereafter over the following four-year period. The grant date for each of the option awards is the
date ten years prior to the option expiration date.
(2) Reflects the aggregate unvested portion of the restricted stock award and RSU grants set forth in the below table.
 Grant Date C. Caldwell A. Valentine C. Twomey C. Gibson J. Fogarty R. Rosso
January 20, 2021
October 5, 2021
January 26, 2022
January 27, 2023
October 27, 2023
February 1, 2024
Total
Previously Vested
Remaining Unvested

Of the restricted stock granted to Mr. Caldwell in 2021, 83,528 shares vests as to 20% on each of the first five anniversaries of
December 1, 2020, the effective date of the spin-off, and 4,594 shares vests as to 20% on each of the first five anniversaries of
October 7, 2020. The restricted stock award granted to Ms. Fogarty in 2021 and the January 2022 and January 2023 restricted
stock awards each vest as to 25% of the shares on each of the first four anniversaries of the grant date. The October 2023
RSU grant and the 2024 RSU grants each vest as to one-third of the shares on each of the first three anniversaries of the grant
date.
(3) The market or payout value of unvested restricted stock, unvested RSUs and unvested PRSUs was determined by multiplying
the number of shares or units shown by $44.95, the closing price of the Common Stock on November 29, 2024, the last trading
day of fiscal year 2024.

(4) For Messrs. Caldwell, Valentine, Twomey, Rosso and Ms. Fogarty, reflects (x) the number of shares of Common Stock that
vested and were settled in January 2025 under each named executive officer's 2022 PRSUs based on the Company's
performance for the three-year performance period ending November 30, 2024, (y) the threshold number of shares of Common
Stock that may vest under each named executive officer's PRSUs granted in January 2023 based on the company's
achievement of below-threshold performance for the first two years of the three-year performance period ending November 30,
2025, and (z) the target number of shares of Common Stock that may vest under each named executive officer's 2024 PRSUs
based on the Company's achievement of above-threshold performance for the first year of the three-year performance period
ending November 30, 2026. For Mr. Gibson, who joined Concentrix in September 2023, reflects the target number of shares of
Common Stock that may vest under Mr. Gibson's February 2024 PRSUs based on the Company's achievement of above-
threshold performance for the first year of the three-year performance period ending November 30, 2026.

TD SYNNEX Equity Awards. In addition to the awards set forth above, Mr. Caldwell has TD
SYNNEX option awards that were granted by TD SYNNEX prior to our spin-off. In connection with the spin-
off, each of these awards was converted into a TD SYNNEX award and a Concentrix award (reflected in
the table above) with respect to the same number of shares as the original award, with an adjustment to the
exercise prices of stock options to preserve the same ratio of the exercise price to the per share value of the
underlying stock as existed prior to the spin-off. Although these awards are issued in TD SYNNEX equity, the
vesting of the awards was based on continued service with Concentrix.

The outstanding TD SYNNEX awards held by Mr. Caldwell as of November 30, 2024 are as follows:

TD SYNNEX Stock Option Awards

Number of Number of
Securities Securities
Underlying Underlying
Unexercised Unexercised Option
Options Options Exercise Option
Exercisable Unexercisable Price Expiration
Name Grant Date (#) (#) ($) Date
Chris Caldwell 10/6/2015
10/4/2016
10/3/2017
10/11/2018
10/2/2019
 OPTION EXERCISES AND STOCK VESTED IN FISCAL YEAR 2024

The following table sets forth the dollar amounts realized pursuant to the vesting or exercise of equity- based
awards by each of our NEOs during the fiscal year ended November 30, 2024.

Option Awards(1)(2) Stock Awards(1)(2)

Number of Shares Value Realized on Number of Shares Value Realized on
Acquired on Exercise Acquired on Vesting Vesting
Name Exercise (#) ($) (#) ($)
Chris Caldwell
Andre Valentine
Cormac Twomey
Craig Gibson
Jane Fogarty
Rick Rosso

(1) The value realized on exercise reflects the in-the-money value of the total number of exercised stock options on the exercise
date and the value realized on vesting reflects the aggregate market value of the total shares of Common Stock vested on the
vesting date. The number of shares acquired and the value realized have not been reduced to reflect the withholding of shares
of Common Stock or the payment of cash for any tax obligation.
(2) Certain of our NEOs exercised TD SYNNEX stock options and vested in the following shares of TD SYNNEX common stock
during fiscal year 2024:

Number of TD
SYNNEX Shares Value Realized on
Acquired on Vesting(a) Vesting(b)
(#) ($)
Chris Caldwell
Andre Valentine
Cormac Twomey
Rick Rosso

(a) See ―Compensation Discussion and Analysis—Historical TD SYNNEX Equity Awards‖ for information about the TD
SYNNEX stock awards previously held by certain of our named executive officers and ―2024 Outstanding Equity Awards
at Fiscal Year-End Table—TD SYNNEX Equity Awards‖ for information about the outstanding TD SYNNEX stock options
held by Mr. Caldwell.
(b) The value realized on vesting reflects the aggregate market value of the total shares of TD SYNNEX common stock
vested on the vesting date. The number of shares acquired and the value realized have not been reduced to reflect the
withholding of shares of TD SYNNEX common stock or the payment of cash for any tax obligation.
 PENSION BENEFITS

The following table sets forth information, as of November 30, 2024, regarding the present value of the
benefits that are expected to be paid to Mr. Valentine under the qualified and non-qualified portion of the
Convergys defined benefit pension plan, which we assumed in our acquisition of Convergys in October
2018. None of our other NEOs participate in qualified or non-qualified defined benefit plans. The Compensation
Committee may elect to adopt qualified or non-qualified defined benefit plans in the future if the Compensation
Committee determines that doing so is in our best interests.

Number of
Years of Present Value
Credited of Accumulated Payments During Last
Service Benefit Fiscal Year
Name Plan Name (#) ($)(1) ($)
Andre Valentine Convergys Corporation Pension Plan
Convergys Corporation Non-Qualified
Excess Pension Plan

(1) The present value of accumulated benefit was determined using a discount rate of 5.09% and assuming a 63% lump sum
payment distribution at age 65 (the normal retirement age specified in the Convergys Corporation Pension Plan).

The Convergys Corporation Pension Plan is a cash-balance pension plan that was open to certain U.S.-
resident employees of Convergys hired prior to April 1, 2007. The plan was frozen effective April 1, 2008, and no
additional pension credits accrue for eligible employees. At the end of each year, active participants' accounts are
credited with interest at the rate of 4% per annum. At retirement or other termination of employment, an amount
equivalent to the balance then credited to the account is payable to the participant in the form of a life annuity.
In lieu of a life annuity, a participant may elect to receive the actuarial equivalent of their benefit in the form of a
lump sum, or a joint and survivor annuity.

The non-qualified excess pension plan provides a pension benefit to employees, including Mr. Valentine,
whose pension benefit under the Pension Plan is reduced or capped due to Internal Revenue Service limitations.
Benefits are paid in ten annual installments or, if less, the number of annual installments (rounded up) equal
to the value of the benefits divided by $50,000, commencing six months after a participant's separation from
service.

POTENTIAL PAYMENTS UPON TERMINATION OR IN CONNECTION WITH A CHANGE OF

CONTROL

The following summarizes the potential payments payable to our NEOs upon termination of employment or a
change of control under individual agreements or the Concentrix Change of Control Severance Plan in effect as of
the end of fiscal year 2024. Although much of the compensation for our NEOs is performance-based and
contingent upon achievement of financial goals, we believe that change of control arrangements provide
important protection to our NEOs, are generally consistent with the practice of our peer companies, and are
appropriate for the attraction and retention of executive talent.

In November 2020, we entered into an offer letter with Mr. Caldwell with respect to his continued
service as our CEO following the spin-off. Under the terms of the offer letter, if Mr. Caldwell's employment is
terminated for a reason other than cause, disability or death and he signs a standard release of claims, he
would be entitled to salary continuation for twelve months at a rate equal to the average of total salary and SMIP
over the prior three years and paid COBRA for 12 months. In addition, under our Change of Control Severance
Plan and Mr. Caldwell's offer letter, if any of Messrs. Caldwell, Valentine, or Rosso or Ms. Fogarty is terminated
for a reason other than cause, disability, or death within two months before or 12 months after a change of
control (including a voluntary termination because of a reduction in salary or position or a relocation) and they sign
a standard release of claims, they would be entitled to salary continuation for a minimum of 18 months plus
one month per year of employment after the eighteenth year of employment, up to a maximum of 24
months, at a rate equal to the average of total salary and SMIP over the prior three years and paid
COBRA for two years. Severance payments for these
 The following table sets forth potential payments payable to our NEOs, under the circumstances described
below, assuming that their employment was terminated or a change of control occurred on November 30, 2024.

Termination
without Cause or
Involuntary
Termination Termination
Voluntary Change of Control; without Cause; No Following Change
Termination No Termination Change of Control of Control
Name Benefit ($) ($) ($) ($)
Chris Caldwell Salary continuation — —

Benefits continuation — —

Equity award vesting — —

Total — —
Andre Valentine Salary continuation — —

Benefits continuation — —

Equity award vesting — —

Total — —
(1)
Cormac Twomey Salary — —

Target SMIP — —

Equity award vesting — —

Total — —
Craig Gibson(1) Salary continuation — —

Equity award vesting — —

Total — —
Jane Fogarty Salary continuation — —

Benefits continuation — —

Equity award vesting — —

Total — —
Rick Rosso Salary continuation — —

Benefits continuation — —

Equity award vesting — —

Total — —